## **ABINGTON**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinar	_			lelanoma of			
Male	9.07	6	66	Male	5.06	7	138
Female	4.00	4	NC*	Female	4.53	7	155
Total	13.07	10	77	Total	9.59	14	146
Brain and Cent				<u>lultiple Mye</u>			N. Cal
Male	3.49	6	172	Male	1.65	3	NC*
Female	3.46	5	145	Female	1.77	0	NC*
Total	6.94	11	158	Total	3.41	3	NC*
<u>Breast</u>					s Lymphom	_	
Male	0.49	0	NC*	Male	7.27	9	124
Female	62.90	48	76	Female	7.13	7	98
Total	63.39	48	76	Total	14.39	16	111
<u>Cervix Uteri</u>			<u>o</u>	ral Cavity a			
				Male	6.63	6	90
Female	4.14	3	NC*	Female	3.20	3	NC*
				Total	9.83	9	92
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	24.07	33	137				
Female	26.89	27	100	Female	7.65	11	144
Total	50.96	60	118				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	3.21	2	NC*	Male	3.41	2	NC*
Female	1.32	2	NC*	Female	4.19	3	NC*
Total	4.54	4	NC*	Total	7.59	5	66
Hodgkin's Dise	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.74	0	NC*	Male	53.13	73	137 #+
Female	1.42	2	NC*				
Total	3.16	2	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>comach</u>			
Male	5.58	1	NC*	Male	4.02	5	124
Female	3.70	0	NC*	Female	2.98	1	NC*
Total	9.28	1	NC*	Total	7.00	6	86
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	3.52	4	NC*	Male	2.66	0	NC*
Female	1.04	0	NC*				
Total	4.55	4	NC*				
<b>Leukemia</b>			<u>T</u>	<u>hyroid</u>			
Male	3.90	2	NC*	Male	1.04	2	NC*
Female	3.32	2	NC*	Female	2.92	1	NC*
Total	7.22	4	NC*	Total	3.96	3	NC*
<b>Liver and Intra</b>	hepatic Bile	<u>Ducts</u>	<u>U</u>	teri, Corpus	and Uterus,	<u>NOS</u>	

Male	1.55	3	NC*				
Female	0.80	1	NC*	Female	11.61	6	52
Total	2.35	4	NC*				
<b>Lung and Bro</b>	nchus		$\mathbf{A}$	ll Sites / Ty			
Male	30.30	41	135	Male	185.22	221	119 #+
Female	23.66	25	106	Female	197.37	170	86
Total	53.96	66	122	Total	382.59	391	102

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## ACTON

## Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>		
Male	9.79	6	61	Male	6.11	8	131
Female	3.65	7	192	Female	5.23	12	230 #+
Total	13.43	13	97	Total	11.33	20	177 #+
<b>Brain and Cen</b>	tral Nervous	<b>System</b>	$\mathbf{M}$	ultiple Mye	<u>eloma</u>		
Male	4.30	6	140	Male	1.83	2	NC*
Female	3.90	7	180	Female	1.68	3	NC*
Total	8.19	13	159	Total	3.51	5	143
<b>Breast</b>			No	on-Hodgkin	's Lymphom	<u>a</u>	
Male	0.56	0	NC*	Male	8.50	10	118
Female	70.15	72	103	Female	7.02	12	171
Total	70.71	72	102	Total	15.51	22	142
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	8.35	5	60
Female	5.05	5	99	Female	3.45	1	NC*
				Total	11.79	6	51
Colon / Rectun	<u>n</u>		<u>O</u>	<u>vary</u>			
Male	26.07	23	88				
Female	23.51	27	115	Female	8.78	4	NC*
Total	49.59	50	101				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	3.86	0	NC*	Male	3.89	2	NC*

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

Female	1.17	0	NC*	Female	3.80	3	NC*	
Total	5.02	0	NC*	Total	7.69	5	65	
Hodgkin's Dis	<u>sease</u>		Ī	<u>Prostate</u>				
Male	2.12	1	NC*	Male	56.69	47	83	
Female	1.69	2	NC*					
Total	3.81	3	NC*					
Kidney and R	enal Pelvis		<u>\$</u>	Stomach .				
Male	6.73	9	134	Male	4.38	6	137	
Female	3.87	2	NC*	Female	2.58	0	NC*	
Total	10.60	11	104	Total	6.96	6	86	
<b>Larynx</b>			<u>Testis</u>					
Male	4.34	0	NC*	Male	3.21	2	NC*	
Female	1.22	0	NC*					
Total	5.56	0	NC*					
Leukemia			7	<u> Chyroid</u>				
Male	4.55	4	NC*	Male	1.30	5	385 #+	
Female	3.40	3	NC*	Female	3.59	4	NC*	
Total	7.96	7	88	Total	4.89	9	184	
Liver and Intr	ahepatic Bile	e Ducts	<u>I</u>	Iteri, Corpu	s and Uter	us, NOS		
Male	1.82	1	NC*					
Female	0.76	1	NC*	Female	13.11	15	114	
Total	2.59	2	NC*					
<b>Lung and Bro</b>	<u>nchu</u> s		<u> </u>	All Sites / T	<u>ypes</u>			
Male	35.13	20	57 ~-	Male	208.91	175	84 #-	
Female	24.86	30	121	Female	206.68	222	107	
Total	60.00	50	83	Total	415.58	397	96	

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### ACUSHNET

## Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<b>SIR</b>
<b>Bladder</b> , Urinary			$\mathbf{M}$	Ielanoma of	<u>Skin</u>		
Male	8.57	1	NC*	Male	4.40	1	NC*
Female	2.89	4	NC*	Female	3.32	0	NC*

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

Total	11.46	5	44	Total	7.73	1	NC*
<b>Brain and Cent</b>	ral Nervous	System	M	ultiple Mye	<u>eloma</u>		
Male	2.90	0	NC*	Male	1.56	0	NC*
Female	2.58	3	NC*	Female	1.31	1	NC*
Total	5.48	3	NC*	Total	2.87	1	NC*
<b>Breast</b>			No	on-Hodgkin	's Lymphom	<u>a</u>	
Male	0.46	0	NC*	Male	6.27	11	175
Female	48.04	43	90	Female	5.20	5	96
Total	48.50	43	89	Total	11.47	16	140
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	6.00	5	83
Female	2.99	2	NC*	Female	2.43	3	NC*
				Total	8.42	8	95
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	22.83	30	131				
Female	19.14	19	99	Female	5.81	3	NC*
Total	41.97	49	117				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	3.02	0	NC*	Male	3.21	4	NC*
Female	0.96	0	NC*	Female	3.07	3	NC*
Total	3.98	0	NC*	Total	6.28	7	111
<b>Hodgkin's Dise</b>	ase		<u>P1</u>	<u>rostate</u>			
Male	1.22	2	NC*	Male	52.12	30	58 ~-
Female	0.96	2	NC*				
Total	2.18	4	NC*				
Kidney and Rei	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	5.15	5	97	Male	3.74	6	160
Female	2.84	0	NC*	Female	2.06	3	NC*
Total	7.99	5	63	Total	5.81	9	155
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	3.30	5	152	Male	1.69	2	NC*
Female	0.84	0	NC*				
Total	4.14	5	121				
<b>Leukemia</b>			<u>Tl</u>	<u>nyroid</u>			
Male	3.37	3	NC*	Male	0.80	1	NC*
Female	2.35	6	255	Female	2.06	1	NC*
Total	5.72	9	157	Total	2.86	2	NC*
Liver and Intra	hepatic Bile	<b>Ducts</b>	<u>U</u> 1	teri, Corpus	and Uterus	, NOS	
Male	1.44	0	NC*				
Female	0.59	1	NC*	Female	9.17	8	87
Total	2.03	1	NC*				
<b>Lung and Brono</b>	<u>chu</u> s		$\underline{\mathbf{A}}$	ll Sites / Ty			
Male	29.03	27	93	Male	172.94	148	86
Female	18.79	13	69	Female	147.98	135	91
Total	47.82	40	84	Total	320.91	283	88 #-

**Obs** = observed case count

Bladder, Urinary

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

**Exp** 

~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<u>Obs</u>

^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

SIR

ADAMS

Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

Melanoma of Skin

<u>SIR</u>

<u>Obs</u>

**Exp** 

	<u>.,,</u>				NO		
Male	9.44	7	74	Male	4.35	2	NC*
Female	3.82	4	NC*	Female	3.70	3	NC*
Total	13.26	11	83	Total	8.06	5	62
<b>Brain and Cent</b>	tral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	Iultiple Mye	eloma		
Male	2.78	2	NC*	Male	1.69	6	355 #+
Female	2.93	4	NC*	Female	1.70	0	NC*
Total	5.70	6	105	Total	3.39	6	177
<b>Breast</b>			<u>N</u>	on-Hodgkin	's Lymphoma	ı	
Male	0.49	1	NC*	Male	6.36	6	94
Female	55.87	51	91	Female	6.54	7	107
Total	56.35	52	92	Total	12.90	13	101
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	5.76	3	NC*
Female	3.13	10	320 ~+	Female	2.88	4	NC*
				Total	8.64	7	81
Colon / Rectum	<u>l</u>		<u>O</u>	<u>vary</u>			
Male	25.07	28	112				
Female	25.89	26	100	Female	6.58	7	106
Total	50.96	54	106				
<b>Esophagus</b>			<u>P</u> :	ancreas			
Male	3.07	8	261 #+	Male	3.37	3	NC*
Female	1.29	2	NC*	Female	4.08	3	NC*
Total	4.36	10	229 #+	Total	7.45	6	81
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.11	0	NC*	Male	57.14	64	112
Female	0.99	2	NC*				
Total	2.10	2	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	tomach			
Male	5.17	2	NC*	Male	4.09	1	NC*
Female	3.45	5	145	Female	2.81	1	NC*
Total	8.62	7	81	Total	6.90	2	NC*

		<u>T</u>	<u>estis</u>					
3.25	2	NC*	Male	1.45	4	NC*		
0.95	1	NC*						
4.20	3	NC*						
		<b>Thyroid</b>						
3.46	3	NC*	Male	0.72	1	NC*		
2.85	7	246	Female	2.12	0	NC*		
6.31	10	159	Total	2.84	1	NC*		
ahepatic Bile I	<u> Ducts</u>	<b>Uteri, Corpus and Uterus, NOS</b>						
1.48	0	NC*						
0.76	1	NC*	Female	10.65	13	122		
2.23	1	NC*						
<u>nchus</u>	pes							
30.16	20	66	Male	182.76	171	94		
22.95	20	87	Female	179.38	185	103		
53.11	40	75	Total	362.14	356	98		
	0.95 4.20 3.46 2.85 6.31 ahepatic Bile I 1.48 0.76 2.23 nchus 30.16 22.95	0.95 1 4.20 3  3.46 3 2.85 7 6.31 10  ahepatic Bile Ducts  1.48 0 0.76 1 2.23 1  nchus  30.16 20 22.95 20	3.25 2 NC* 0.95 1 NC* 4.20 3 NC*  3.46 3 NC*  2.85 7 246 6.31 10 159  ahepatic Bile Ducts  1.48 0 NC* 0.76 1 NC* 2.23 1 NC*  achus  30.16 20 66 22.95 20 87	0.95       1       NC*         4.20       3       NC*         Thyroid         3.46       3       NC*       Male         2.85       7       246       Female         6.31       10       159       Total         All Sites / Corpus         1.48       0       NC*         0.76       1       NC*       Female         2.23       1       NC*         nchus       All Sites / Ty         30.16       20       66       Male         22.95       20       87       Female	3.25 2 NC* Male 1.45 0.95 1 NC* 4.20 3 NC*  Thyroid  3.46 3 NC* Male 0.72 2.85 7 246 Female 2.12 6.31 10 159 Total 2.84  ahepatic Bile Ducts  1.48 0 NC*  0.76 1 NC*  0.76 1 NC* Female 10.65 2.23 1 NC*  achus  30.16 20 66 Male 182.76 22.95 20 87 Female 179.38	3.25 2 NC* Male 1.45 4 0.95 1 NC* 4.20 3 NC*  Thyroid  3.46 3 NC* Male 0.72 1 2.85 7 246 Female 2.12 0 6.31 10 159 Total 2.84 1  ahepatic Bile Ducts  1.48 0 NC*  0.76 1 NC* Female 10.65 13 2.23 1 NC*  achus  All Sites / Types  30.16 20 66 Male 182.76 171 22.95 20 87 Female 179.38 185		

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

#### **AGAWAM**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	Obs	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>			
Male	22.25	18	81	Male	11.34	10	88	
Female	9.06	6	66	Female	9.74	7	72	
Total	31.31	24	77	Total	21.08	17	81	
<b>Brain and Cent</b>	tral Nervous S	<u>System</u>	<u>ystem</u> <u>Multiple Myeloma</u>					
Male	7.49	6	80	Male	3.99	5	125	
Female	7.44	9	121	Female	4.00	7	175	
Total	14.93	15	100	Total	8.00	12	150	
<b>Breast</b>			No	on-Hodgkin	's Lymphom	<u>a</u>		
Male	1.18	1	NC*	Male	16.36	13	79	
Female	138.90	126	91	Female	15.86	13	82	
Total	140.08	127	91	Total	32.21	26	81	
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx			

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

				Male	14.90	14	94	
Female	8.70	7	80	Female	7.12	4	NC*	
				Total	22.02	18	82	
Colon / Rectur	<u>m</u>		<u>O</u>	<u>vary</u>				
Male	58.93	62	105					
Female	60.93	55	90	Female	16.69	14	84	
Total	119.86	117	98					
<b>Esophagus</b>			<u>Pa</u>	ancreas				
Male	7.53	4	NC*	Male	8.12	1	NC*	
Female	3.02	0	NC*	Female	9.50	4	NC*	
Total	10.55	4	NC*	Total	17.62	5	28 ^-	
Hodgkin's Di	sease		<u>Pı</u>	<u>rostate</u>				
Male	3.42	5	146	Male	131.46	94	72 ^-	
Female	2.86	1	NC*					
Total	6.28	6	95					
Kidney and R	enal Pelvis		St	<u>omach</u>				
Male	12.81	5	39 #-	Male	9.79	10	102	
Female	8.26	4	NC*	Female	6.71	5	74	
Total	21.07	9	43 ~-	Total	16.50	15	91	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				
Male	8.11	6	74	Male	4.99	4	NC*	
Female	2.33	1	NC*					
Total	10.44	7	67					
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>				
Male	8.79	7	80	Male	2.12	3	NC*	
Female	7.15	5	70	Female	6.04	7	116	
Total	15.94	12	75	Total	8.15	10	123	
<b>Liver and Int</b>	ahepatic Bile	<u>Ducts</u>	<u>U1</u>	teri, Corpus	s and Uterus.	, NOS		
Male	3.62	2	NC*					
Female	1.80	1	NC*	Female	25.93	22	85	
Total	5.42	3	NC*					
<b>Lung and Bro</b>	<u>nchu</u> s		$\underline{\mathbf{A}}$	ll Sites / Ty	pes			
Male	72.03	63	87	Male	440.15	364	83 ^-	
Female	53.52	53	99	Female	438.32	375	86 ~-	
Total	125.55	116	92	Total	878.47	739	84 ^-	

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## ALFORD

## Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				<u>lelanoma of</u>			
Male	0.56	0	NC*	Male	0.24	1	NC*
Female	0.16	0	NC*	Female	0.15	0	NC*
Total	0.72	0	NC*	Total	0.39	1	NC*
<b>Brain and Central</b>				<u>Iultiple Mye</u>			
Male	0.14	0	NC*	Male	0.10	0	NC*
Female	0.12	0	NC*	Female	0.07	0	NC*
Total	0.26	0	NC*	Total	0.17	0	NC*
<b>Breast</b>			<u>N</u>	on-Hodgkin'	s Lymphom	<u>a</u>	
Male	0.03	1	NC*	Male	0.35	0	NC*
Female	2.30	0	NC*	Female	0.27	0	NC*
Total	2.33	1	NC*	Total	0.61	0	NC*
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	0.32	0	NC*
Female	0.12	0	NC*	Female	0.12	0	NC*
				Total	0.44	0	NC*
Colon / Rectum			<u>O</u>	vary			
Male	1.48	0	NC*				
Female	1.06	0	NC*	Female	0.27	0	NC*
Total	2.54	0	NC*				
Esophagus			P	ancreas			
Male	0.18	0	NC*	Male	0.19	0	NC*
Female	0.05	0	NC*	Female	0.17	0	NC*
Total	0.23	0	NC*	Total	0.36	0	NC*
Hodgkin's Disease	e		P	rostate			
Male	0.05	0	NC*	Male	3.17	1	NC*
Female	0.04	0	NC*				
Total	0.08	0	NC*				
Kidney and Renal			St	tomach			
Male	0.28	0	NC*	Male	0.25	0	NC*
Female	0.14	0	NC*	Female	0.12	0	NC*
Total	0.42	0	NC*	Total	0.36	0	NC*
Larynx		_		estis		-	
Male	0.18	0	NC*	Male	0.05	0	NC*
Female	0.04	0	NC*		****		
Total	0.22	0	NC*				
Leukemia	0.22	· ·		hyroid			
Male	0.19	0	NC*	Male	0.03	0	NC*
Female	0.12	0	NC*	Female	0.03	0	NC*
Total	0.12	0	NC*	Total	0.00	0	NC*
Liver and Intrahe		_		teri, Corpus			110

Male	0.08	0	NC*				
Female	0.03	0	NC*	Female	0.44	0	NC*
Total	0.11	0	NC*				
<b>Lung and Bron</b>	nchus	<u>oes</u>					
Male	1.66	0	NC*	Male	10.23	3	NC*
Female	0.93	1	NC*	Female	7.33	2	NC*
Total	2.59	1	NC*	Total	17.57	5	28 ^-

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **AMESBURY**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		$\mathbf{M}$	lelanoma of	<u>Skin</u>			
Male	9.04	14	155	Male	5.09	4	NC*	
Female	3.96	3	NC*	Female	4.65	3	NC*	
Total	13.00	17	131	Total	9.74	7	72	
<b>Brain and Cen</b>	tral Nervous	<u>System</u>	$\mathbf{M}$	lultiple Mye	<u>loma</u>			
Male	3.57	7	196	Male	1.65	2	NC*	
Female	3.52	1	NC*	Female	1.73	0	NC*	
Total	7.08	8	113	Total	3.38	2	NC*	
<b>Breast</b>			No	on-Hodgkin	's Lymphom	<u>a</u>		
Male	0.49	0	NC*	Male	7.38	10	136	
Female	62.36	67	107	Female	7.13	10	140	
Total	62.86	67	107	Total	14.51	20	138	
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx			
				Male	6.53	6	92	
Female	4.38	5	114	Female	3.17	2	NC*	
				Total	9.69	8	83	
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	23.97	27	113					
Female	26.61	22	83	Female	7.67	6	78	
Total	50.58	49	97					
<b>Esophagus</b>	Pancreas Pancreas							
Male	3.16	6	190	Male	3.36	7	208	

1 Ciliaic	1.51	U	IVC	Temate	7.11	7	IVC
Total	4.47	6	134	Total	7.47	11	147
Hodgkin's Dise	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.85	0	NC*	Male	52.06	59	113
Female	1.58	0	NC*				
Total	3.43	0	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	omach			
Male	5.53	5	90	Male	4.02	7	174
Female	3.65	6	165	Female	2.97	1	NC*
Total	9.18	11	120	Total	6.99	8	114
<u>Larynx</u>			$\mathbf{T}$	<u>estis</u>			
Male	3.43	4	NC*	Male	2.86	3	NC*
Female	1.00	1	NC*				
Total	4.43	5	113				
<b>Leukemia</b>			<u>T</u>	<u>hyroid</u>			
Male	3.99	4	NC*	Male	1.07	1	NC*
Female	3.40	7	206	Female	3.15	3	NC*
Total	7.39	11	149	Total	4.22	4	NC*
<b>Liver and Intra</b>	hepatic Bile I	<u>Ducts</u>	$\underline{\mathbf{U}}$	teri, Corpus	and Uterus,	NOS	
Male	1.54	2	NC*				
Female	0.80	0	NC*	Female	11.32	13	115
Total	2.34	2	NC*				
<b>Lung and Bron</b>	<u>chu</u> s		<u>A</u>	ll Sites / Ty	pes		
Male	29.75	37	124	Male	183.96	215	117 #+
Female	22.92	21	92	Female	196.15	187	95
Total	52.66	58	110	Total	380.11	402	106

NC\*

Female

4.11

NC\*

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

Female

1.31

0

#### **AMHERST**

## Cancer Incidence by Sex, 1990 - 1995

	<b>Exp</b>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<b>SIR</b>
Bladder, Urinar	<b>y</b>		$\mathbf{M}$				
Male	11.72	9	77	Male	8.26	3	NC*
Female	4.52	4	NC*	Female	7.96	4	NC*

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

Total	16.24	13	80	Total	16.22	7	43 #-
<b>Brain and Cent</b>	ral Nervous	System	<u>M</u>	ultiple My	<u>eloma</u>		
Male	6.45	4	NC*	Male	2.15	4	NC*
Female	5.89	4	NC*	Female	2.01	1	NC*
Total	12.34	8	65	Total	4.16	5	120
<b>Breast</b>			No	on-Hodgkin	's Lymphon	<u>na</u>	
Male	0.67	0	NC*	Male	12.40	6	48
Female	89.63	96	107	Female	9.64	12	124
Total	90.30	96	106	Total	22.04	18	82
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	9.50	4	NC*
Female	8.69	2	NC*	Female	4.31	4	NC*
				Total	13.81	8	58
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	31.07	22	71				
Female	29.69	25	84	Female	11.93	8	67
Total	60.76	47	77				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	4.13	1	NC*	Male	4.51	3	NC*
Female	1.43	0	NC*	Female	4.66	2	NC*
Total	5.56	1	NC*	Total	9.16	5	55
Hodgkin's Dise	ease		<u>P1</u>	<u>rostate</u>			
Male	4.37	1	NC*	Male	64.44	52	81
Female	3.65	0	NC*				
Total	8.03	1	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	7.86	4	NC*	Male	5.38	2	NC*
Female	4.93	0	NC*	Female	3.35	0	NC*
Total	12.79	4	NC*	Total	8.73	2	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	4.55	2	NC*	Male	7.62	5	66
Female	1.32	1	NC*				
Total	5.87	3	NC*				
<b>Leukemia</b>			<u>Tl</u>	<u>nyroid</u>			
Male	6.60	4	NC*	Male	2.23	4	NC*
Female	5.37	4	NC*	Female	6.66	2	NC*
Total	11.96	8	67	Total	8.89	6	67
<b>Liver and Intra</b>	hepatic Bile	Ducts	<u>U</u> 1	teri, Corpus	s and Uterus	s, NOS	
Male	2.17	0	NC*				
Female	1.02	0	NC*	Female	15.27	11	72
Total	3.19	0	NC*				
<b>Lung and Bron</b>	<u>chu</u> s		$\underline{\mathbf{A}}$	ll Sites / Ty	pes		
Male	38.56	11	29 ^-	Male	256.38	156	61 ^-
Female	28.92	14	48 ~-	Female	270.29	210	78 ^-
Total	67.48	25	37 ^-	Total	526.67	366	69 ^-

**Obs** = observed case count

**Bladder**. Urinary

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

**Exp** 

~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

Obs

^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

**SIR** 

## **ANDOVER**

## Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

Melanoma of Skin

E<u>xp</u>

Obs

<u>SIR</u>

Bladder, Urina	<u>ry</u>		M	<u>elanoma of</u>	Skin		
Male	18.73	17	91	Male	10.59	16	151
Female	7.27	10	138	Female	9.11	6	66
Total	26.00	27	104	Total	19.70	22	112
<b>Brain and Cen</b>	tral Nervous	<b>System</b>	$\mathbf{M}$	ultiple My	eloma		
Male	7.29	12	165	Male	3.46	6	173
Female	6.96	13	187	Female	3.32	1	NC*
Total	14.26	25	175 #+	Total	6.78	7	103
<b>Breast</b>				on-Hodgkin	's Lymphom	<u>a</u>	
Male	1.04	1	NC*	Male	14.86	16	108
Female	128.12	166	130 ~+	Female	13.39	17	127
Total	129.16	167	129 ~+	Total	28.25	33	117
Cervix Uteri			<u>O</u>	ral Cavity a	<u>nd Pharynx</u>		
				Male	14.59	15	103
Female	8.41	8	95	Female	6.40	4	NC*
				Total	20.99	19	91
Colon / Rectun			<u>O</u>	<u>vary</u>			
Male	49.94	62	124				
Female	47.64	63	132 #+	Female	15.71	19	121
Total	97.57	125	128 ~+				
<b>Esophagus</b>				ancreas			
Male	7.04	5	71	Male	7.24	5	69
Female	2.37	3	NC*	Female	7.65	13	170
Total	9.41	8	85	Total	14.90	18	121
<b>Hodgkin's Dis</b>				<u>rostate</u>			
Male	3.27	2	NC*	Male	111.37	137	123 #+
Female	2.73	1	NC*				
Total	6.01	3	NC*				
Kidney and Re				<u>omach</u>			
Male	12.14	10	82	Male	8.27	6	73
Female	7.35	6	82	Female	5.18	1	NC*
Total	19.48	16	82	Total	13.45	7	52

<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	7.81	5	64	Male	4.63	10	216 #+
Female	2.25	0	NC*				
Total	10.06	5	50				
Leukemia			<u>T</u>	hyroid			
Male	8.11	12	148	Male	2.07	3	NC*
Female	6.25	8	128	Female	5.87	6	102
Total	14.36	20	139	Total	7.94	9	113
<b>Liver and Intr</b>	ahepatic Bile l	<u>Ducts</u>	$\mathbf{U}_{1}$	teri, Corpus	s and Uterus,	NOS	
			4.50				
Male	3.33	5	150				
Male Female	3.33 1.50	5 1	150 NC*	Female	24.27	22	91
				Female	24.27	22	91
Female	1.50 4.82	1	NC* 124	Female		22	91
Female Total	1.50 4.82	1	NC* 124			22 423	91 109
Female Total Lung and Bro	1.50 4.82 <b>nchus</b>	1 6	NC* 124 <u><b>A</b></u>	ll Sites / Ty	pes		
Livei and mu	•			cer, corpus	s and Ottius,	1100	

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

#### **ARLINGTON**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	Obs	SIR	
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	lelanoma of	Skin			
Male	37.05	26	70	Male	18.45	23	125	
Female	16.68	21	126	Female	17.20	28	163 #+	
Total	53.72	47	87	Total	35.65	51	143 #+	
<b>Brain and Cen</b>	ntral Nervous System Multiple Myeloma							
Male	11.88	15	126	Male	6.65	10	150	
Female	13.04	17	130	Female	7.35	3	NC*	
Total	24.92	32	128	Total	14.00	13	93	
<b>Breast</b>			No	on-Hodgkin	<u>'s Lymphoma</u>			
Male	1.95	1	NC*	Male	26.72	28	105	
Female	248.26	281	113 #+	Female	28.87	23	80	
Total	250.21	282	113	Total	55.60	51	92	
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx			

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

				Male	24.06	20	83	
Female	15.19	6	39 #-	Female	12.74	10	79	
				Total	36.80	30	82	
Colon / Rectur	<u>n</u>		<u>O</u>	<u>vary</u>				
Male	98.22	95	97	<u></u>				
Female	112.99	121	107	Female	29.58	36	122	
Total	211.21	216	102					
<b>Esophagus</b>			<u>Pa</u>	ancreas				
Male	12.33	7	57	Male	13.42	9	67	
Female	5.59	2	NC*	Female	17.57	20	114	
Total	17.92	9	50 #-	Total	30.99	29	94	
Hodgkin's Dis	<u>sease</u>		<u>P</u> 1	<u>rostate</u>				
Male	5.35	6	112	Male	220.02	268	122 ~+	
Female	4.92	9	183					
Total	10.27	15	146					
Kidney and R	enal Pelvis		<u>St</u>	omach				
Male	20.95	15	72	Male	16.23	15	92	
Female	14.89	10	67	Female	12.44	12	96	
Total	35.83	25	70	Total	28.67	27	94	
<b>Larynx</b>			<u>Te</u>	<u>estis</u>				
Male	13.18	10	76	Male	7.93	19	240 ~+	
Female	4.12	3	NC*					
Total	17.29	13	75					
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>				
Male	14.09	13	92	Male	3.39	5	147	
Female	12.68	6	47	Female	10.46	13	124	
Total	26.77	19	71	Total	13.85	18	130	
<b>Liver and Intr</b>	ahepatic Bile	<u>Ducts</u>		teri, Corpus	and Uterus,	<b>NOS</b>		
Male	5.94	5	84					
Female	3.27	6	183	Female	46.30	46	99	
Total	9.21	11	119					
<b>Lung and Bro</b>	<u>nchu</u> s		$\mathbf{A}$	ll Sites / Ty				
Male	119.12	108	91	Male	727.52	749	103	
Female	97.23	78	80	Female	790.89	807	102	
Total	216.35	186	86 #-	Total	1518.41	1556	102	

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## **ASHBURNHAM**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		<b>Exp</b>	Obs	SIR
Bladder, Urinar	<u>Y</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	3.48	6	173	Male	1.98	0	NC*
Female	0.92	0	NC*	Female	1.42	0	NC*
Total	4.40	6	136	Total	3.40	0	NC*
<b>Brain and Cent</b>	ral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	Iultiple Mye	<u>loma</u>		
Male	1.41	0	NC*	Male	0.64	1	NC*
Female	1.07	0	NC*	Female	0.42	0	NC*
Total	2.48	0	NC*	Total	1.06	1	NC*
<b>Breast</b>			N	on-Hodgkin	s Lymphom	<u>a</u>	
Male	0.19	0	NC*	Male	2.85	3	NC*
Female	17.99	21	117	Female	1.85	0	NC*
Total	18.18	21	116	Total	4.70	3	NC*
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	2.62	0	NC*
Female	1.44	5	348 #+	Female	0.88	0	NC*
				Total	3.49	0	NC*
Colon / Rectum			<u>o</u>	vary			
Male	9.26	10	108				
Female	5.97	1	NC*	Female	2.30	2	NC*
Total	15.24	11	72				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	1.26	1	NC*	Male	1.33	0	NC*
Female	0.29	0	NC*	Female	0.97	2	NC*
Total	1.56	1	NC*	Total	2.29	2	NC*
<b>Hodgkin's Dise</b>	<u>ase</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.70	1	NC*	Male	20.60	16	78
Female	0.54	0	NC*				
Total	1.24	1	NC*				
Kidney and Rer	nal Pelvis		<u>St</u>	tomach			
Male	2.22	2	NC*	Male	1.54	1	NC*
Female	1.01	2	NC*	Female	0.65	1	NC*
Total	3.22	4	NC*	Total	2.19	2	NC*
<b>Larynx</b>			<u>T</u>	<u>estis</u>			
Male	1.39	0	NC*	Male	1.04	0	NC*
Female	0.30	0	NC*				
Total	1.69	0	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	1.57	0	NC*	Male	0.41	1	NC*
Female	0.95	1	NC*	Female	1.05	1	NC*
Total	2.51	1	NC*	Total	1.47	2	NC*
<b>Liver and Intral</b>	hepatic Bile	<u>Ducts</u>	<u>U</u>	teri, Corpus	and Uterus,	NOS	

Male	0.61	0	NC*				
Female	0.20	0	NC*	Female	3.29	0	NC*
Total	0.81	0	NC*				
<b>Lung and Bro</b>	nchus		<u>A</u> ]	ll Sites / Ty	pes		
Male	11.93	12	101	Male	72.30	56	77
Female	6.32	7	111	Female	53.54	46	86
Total	18.26	19	104	Total	125.84	102	81 #-

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## ASHBY Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>.y</u>		$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>		
Male	1.62	2	NC*	Male	0.95	1	NC*
Female	0.57	0	NC*	Female	0.76	0	NC*
Total	2.19	2	NC*	Total	1.71	1	NC*
<b>Brain and Cent</b>	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	lultiple Mye	<u>loma</u>		
Male	0.68	0	NC*	Male	0.30	1	NC*
Female	0.59	1	NC*	Female	0.26	0	NC*
Total	1.27	1	NC*	Total	0.55	1	NC*
<b>Breast</b>			N	on-Hodgkin'	s Lymphom	<u>a</u>	
Male	0.09	0	NC*	Male	1.35	0	NC*
Female	10.23	14	137	Female	1.08	1	NC*
Total	10.32	14	136	Total	2.44	1	NC*
Cervix Uteri			0	ral Cavity ar	nd Pharynx		
				Male	1.27	1	NC*
Female	0.74	2	NC*	Female	0.51	0	NC*
				Total	1.78	1	NC*
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>			
Male	4.31	9	209				
Female	3.74	9	241 #+	Female	1.28	1	NC*
Total	8.05	18	224 ~+				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	0.60	0	NC*	Male	0.63	0	NC*

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

Total	0.79	0	NC*	Total	1.23	0	NC*
<b>Hodgkin's Dise</b>	ase		<u>P</u> 1	<u>rostate</u>			
Male	0.34	0	NC*	Male	9.79	11	112
Female	0.26	0	NC*				
Total	0.60	0	NC*				
Kidney and Rei	nal Pelvis		St	omach_			
Male	1.06	2	NC*	Male	0.72	1	NC*
Female	0.59	0	NC*	Female	0.41	1	NC*
Total	1.64	2	NC*	Total	1.12	2	NC*
<b>Larynx</b>			<u>T</u>	<u>estis</u>			
Male	0.67	1	NC*	Male	0.51	0	NC*
Female	0.17	0	NC*				
Total	0.85	1	NC*				
Leukemia			<u>T</u>	hyroid			
Male	0.74	0	NC*	Male	0.20	0	NC*
Female	0.53	0	NC*	Female	0.53	1	NC*
Total	1.28	0	NC*	Total	0.73	1	NC*
<b>Liver and Intra</b>	hepatic Bile D	<u>ucts</u>	$\mathbf{U}_{1}$	teri, Corpus	and Uterus,	<b>NOS</b>	
Male	0.29	0	NC*				
Female	0.12	1	NC*	Female	1.90	5	263
Total	0.41	1	NC*				
<b>Lung and Brono</b>	<u>chus</u>		<u>A</u>	ll Sites / Typ	<u>oes</u>		
Male	5.68	5	88	Male	34.27	36	105
Female	3.76	2	NC*	Female	31.04	38	122
Total	9.44	7	74	Total	65.31	74	113

NC\*

Female

0.60

0

NC\*

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

Female

0.19

0

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

## **ASHFIELD**

## Cancer Incidence by Sex, 1990 - 1995

	<b>Exp</b>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>
<b>Bladder</b> , Urinary			$\mathbf{M}$	lelanoma of	<u>Skin</u>		
Male	1.48	3	NC*	Male	0.73	0	NC*
Female	0.39	0	NC*	Female	0.52	3	NC*

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} <= 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

T-4-1	1.07	2	NOV	T-4-1	1.05	2	NOΨ	
Total	1.87	3	NC*	Total	1.25	3	NC*	
Brain and Centr				<u>lultiple Mye</u>		0	NICH	
Male	0.48	0	NC*	Male	0.26	0	NC*	
Female	0.39	1	NC*	Female	0.18	0	NC*	
Total	0.87	1	NC*	Total	0.44	0	NC*	
<u>Breast</u>	0.00				's Lymphoma	•		
Male	0.08	0	NC*	Male	1.07	0	NC*	
Female	6.97	8	115	Female	0.74	0	NC*	
Total	7.05	8	114	Total	1.80	0	NC*	
Cervix Uteri			<u>O</u>	ral Cavity a				
				Male	0.93	0	NC*	
Female	0.50	1	NC*	Female	0.35	0	NC*	
				Total	1.27	0	NC*	
Colon / Rectum			<u>o</u>	<u>vary</u>				
Male	3.91	0	NC*					
Female	2.54	5	197	Female	0.87	1	NC*	
Total	6.44	5	78					
<b>Esophagus</b>			<u>Pa</u>	ancreas				
Male	0.48	1	NC*	Male	0.52	0	NC*	
Female	0.13	1	NC*	Female	0.41	0	NC*	
Total	0.61	2	NC*	Total	0.93	0	NC*	
<b>Hodgkin's Dise</b>	<u>ase</u>		<u>P</u> 1	<u>rostate</u>				
Male	0.22	0	NC*	Male	8.47	8	94	
Female	0.17	0	NC*					
Total	0.40	0	NC*					
Kidney and Rer	nal Pelvis		St	omach				
Male	0.81	1	NC*	Male	0.65	1	NC*	
Female	0.40	0	NC*	Female	0.28	0	NC*	
Total	1.21	1	NC*	Total	0.93	1	NC*	
Larynx			To	estis				
Male	0.50	0	NC*	Male	0.33	0	NC*	
Female	0.12	0	NC*					
Total	0.62	0	NC*					
<b>Leukemia</b>				hyroid				
Male	0.58	0	NC*	Male	0.13	0	NC*	
Female	0.35	0	NC*	Female	0.36	0	NC*	
Total	0.93	0	NC*	Total	0.49	0	NC*	
Liver and Intral					and Uterus,		-,-	
Male	0.23	0	NC*	<del></del>		1,00		
Female	0.08	0	NC*	Female	1.30	2	NC*	
Total	0.31	0	NC*	1 ciricio	1.00	_	1,0	
Lung and Brone		J		ll Sites / Ty	nes			
Male	4.57	5	109	Male	28.47	20	70	
Female	2.59	1	NC*	Female	21.10	26	123	
Total	7.16	6	84	Total	49.58	46	93	
Total	7.10	<u> </u>	υ <del>1</del>	10tai	<del>-</del> 7.30	<del>1</del> 0		

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## **ASHLAND**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	<u>SIR</u>		<b>Exp</b>	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>			
Male	7.56	8	106	Male	4.49	10	223 #+	
Female	2.62	4	NC*	Female	3.83	7	183	
Total	10.19	12	118	Total	8.32	17	204 #+	
<b>Brain and Cen</b>	tral Nervous	s System	$\mathbf{M}$	<b>Sultiple Mye</b>	eloma			
Male	3.12	4	NC*	Male	1.39	1	NC*	
Female	2.83	5	177	Female	1.21	3	NC*	
Total	5.94	9	151	Total	2.60	4	NC*	
<b>Breast</b>			Non-Hodgkin's Lymphoma					
Male	0.42	0	NC*	Male	6.45	10	155	
Female	50.07	47	94	Female	5.14	3	NC*	
Total	50.49	47	93	Total	11.59	13	112	
Cervix Uteri			<u>o</u>	ral Cavity a	nd Pharynx			
				Male	5.79	3	NC*	
Female	3.82	9	236 #+	Female	2.45	1	NC*	
				Total	8.23	4	NC*	
Colon / Rectun	<u>1</u>		<u>o</u>	vary				
Male	20.13	15	75					
Female	17.01	19	112	Female	6.30	5	79	
Total	37.15	34	92					
<b>Esophagus</b>			<u>Pa</u>	ancreas				
Male	2.74	4	NC*	Male	2.89	3	NC*	
Female	0.85	0	NC*	Female	2.77	5	181	
Total	3.58	4	NC*	Total	5.66	8	141	
<b>Hodgkin's Dis</b>	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	1.66	3	NC*	Male	44.15	48	109	
Female	1.34	1	NC*					
Total	3.01	4	NC*					
Kidney and Re	enal Pelvis		St	tomach				
Male	4.82	3	NC*	Male	3.37	3	NC*	
Female	2.80	5	178	Female	1.84	4	NC*	
Total	7.63	8	105	Total	5.21	7	134	

<b>Larynx</b>			<u>T</u>	<u>estis</u>			
Male	3.01	2	NC*	Male	2.70	1	NC*
Female	0.85	0	NC*				
Total	3.86	2	NC*				
<b>Leukemia</b>			<u>T</u>	hyroid			
Male	3.37	3	NC*	Male	0.98	0	NC*
Female	2.45	2	NC*	Female	2.74	1	NC*
Total	5.81	5	86	Total	3.73	1	NC*
Liver and Intr	<u>ahepatic Bile D</u>	<u>ucts</u>	$\underline{\mathbf{U}}_1$	teri, Corpus	s and Uterus,	NOS	
Liver and Intr Male	tahepatic Bile D 1.33	<u>oucts</u> 1	NC*	teri, Corpus	s and Uterus,	<u>NOS</u>	
				<b>teri, Corpus</b> Female	s and Uterus, 9.27	<b>NOS</b> 10	108
Male	1.33	1	NC*	-			108
Male Female	1.33 0.56 1.89	1 1	NC* NC* NC*	-	9.27		108
Male Female Total	1.33 0.56 1.89	1 1	NC* NC* NC*	Female	9.27		108 99
Male Female Total Lung and Bro	1.33 0.56 1.89 <b>nchus</b>	1 1 2	NC* NC* NC*	Female	9.27 <b>pes</b>	10	
Male Female Total Lung and Brown Male	1.33 0.56 1.89 <b>nchus</b> 25.74	1 1 2 24	NC* NC* NC* <u>Al</u> 93	Female  Il Sites / Ty  Male	9.27 <u>pes</u> 157.82	10 156	99

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

ATHOL

Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>		
Male	9.33	11	118	Male	4.54	7	154
Female	3.78	3	NC*	Female	3.88	8	206
Total	13.11	14	107	Total	8.42	15	178
<b>Brain and Cent</b>	tral Nervous System Multiple Myeloma						
Male	3.02	3	NC*	Male	1.67	1	NC*
Female	3.04	5	164	Female	1.66	3	NC*
Total	6.07	8	132	Total	3.33	4	NC*
<b>Breast</b>			No	on-Hodgkin	s Lymphom	<u>a</u>	
Male	0.49	0	NC*	Male	6.63	5	75
Female	55.96	55	98	Female	6.55	9	137
Total	56.45	55	97	Total	13.18	14	106
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

				Male	5.90	5	85	
Female	3.40	6	176	Female	2.89	2	NC*	
				Total	8.79	7	80	
Colon / Rectur	<u>m</u>		0	<u>vary</u>				
Male	24.67	27	109					
Female	25.60	22	86	Female	6.69	5	75	
Total	50.27	49	97					
<b>Esophagus</b>			<u>Pa</u>	ancreas				
Male	3.06	1	NC*	Male	3.33	2	NC*	
Female	1.27	1	NC*	Female	3.98	3	NC*	
Total	4.33	2	NC*	Total	7.31	5	68	
Hodgkin's Di	sease		<u>P</u> 1	<u>rostate</u>				
Male	1.35	1	NC*	Male	54.67	45	82	
Female	1.15	1	NC*					
Total	2.50	2	NC*					
Kidney and R	<u>Renal Pelvis</u>		St	<u>omach</u>				
Male	5.19	3	NC*	Male	4.09	3	NC*	
Female	3.40	5	147	Female	2.82	4	NC*	
Total	8.59	8	93	Total	6.91	7	101	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	3.24	7	216	Male	1.86	1	NC*	
Female	0.93	0	NC*					
Total	4.17	7	168					
<u>Leukemia</u>			<u>T</u>	<u>nyroid</u>				
Male	3.67	6	164	Male	0.82	1	NC*	
Female	3.00	1	NC*	Female	2.37	1	NC*	
Total	6.66	7	105	Total	3.19	2	NC*	
<b>Liver and Int</b>	rahepatic Bile l	<u>Ducts</u>		teri, Corpus	s and Uterus,	<b>NOS</b>		
Male	1.48	2	NC*					
Female	0.75	1	NC*	Female	10.45	13	124	
Total	2.23	3	NC*					
<b>Lung and Bro</b>	<u>nchu</u> s		$\mathbf{A}$	ll Sites / Ty	pes			
Male	29.42	35	119	Male	181.18	177	98	
Female	21.97	22	100	Female	179.19	177	99	
Total	51.39	57	111	Total	360.37	354	98	

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## ATTLEBORO

## Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	Obs	SIR
Bladder, Urina				<u> Ielanoma of</u>			
Male	25.71	22	86	Male	14.10	6	43 #-
Female	9.96	7	70	Female	11.98	15	125
Total	35.67	29	81	Total	26.07	21	81
<b>Brain and Cen</b>				<u>Iultiple Mye</u>			
Male	9.75	11	113	Male	4.66	10	214 #+
Female	9.19	6	65	Female	4.46	3	NC*
Total	18.93	17	90	Total	9.13	13	142
<b>Breast</b>			<u>N</u>	on-Hodgkin	<u>'s Lymphoma</u>	1	
Male	1.39	0	NC*	Male	20.44	20	98
Female	164.28	173	105	Female	18.21	21	115
Total	165.67	173	104	Total	38.64	41	106
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	18.23	14	77
Female	11.24	13	116	Female	8.29	6	72
				Total	26.52	20	75
Colon / Rectum	<u>1</u>		<u>O</u>	vary			
Male	68.26	59	86				
Female	66.34	68	103	Female	20.16	25	124
Total	134.60	127	94				
<b>Esophagus</b>			<u>P</u> :	<u>ancreas</u>			
Male	8.92	15	168	Male	9.58	7	73
Female	3.29	9	273 #+	Female	10.50	7	67
Total	12.22	24	196 ~+	Total	20.08	14	70
Hodgkin's Dis	ease		<u>P</u> 1	<u>rostate</u>			
Male	4.91	8	163	Male	151.42	117	77 ~-
Female	3.94	7	178				
Total	8.85	15	170				
Kidney and Re	enal Pelvis		St	tomach_			
Male	15.55	16	103	Male	11.37	13	114
Female	9.67	11	114	Female	7.25	9	124
Total	25.21	27	107	Total	18.62	22	118
Larynx			$\mathbf{T}$	estis			
Male	9.70	11	113	Male	7.53	11	146
Female	2.76	4	NC*				
Total	12.46	15	120				
Leukemia			$\mathbf{T}$	hyroid			
Male	11.01	15	136	Male	2.89	6	208
Female	8.55	10	117	Female	7.98	6	75
Total	19.56	25	128	Total	10.87	12	110
Liver and Intra					and Uterus,		- 0

Male	4.35	4	NC*				
Female	2.05	2	NC*	Female	30.55	27	88
Total	6.40	6	94				
<b>Lung and Bro</b>	nchus		<u>A</u> ]	ll Sites / Ty	pes		
Male	85.05	89	105	Male	522.77	493	94
Female	62.37	71	114	Female	510.18	546	107
Total	147.41	160	109	Total	1032.95	1039	101

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## **AUBURN**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ry</u>		$\mathbf{M}$	lelanoma of	<u>Skin</u>			
Male	14.07	11	78	Male	6.95	6	86	
Female	4.85	3	NC*	Female	5.37	6	112	
Total	18.91	14	74	Total	12.32	12	97	
<b>Brain and Cen</b>	tral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	lultiple Mye	<u>eloma</u>			
Male	4.51	3	NC*	Male	2.54	0	NC*	
Female	4.17	4	NC*	Female	2.20	2	NC*	
Total	8.68	7	81	Total	4.73	2	NC*	
<b>Breast</b>		Non-Hodgkin's Lymphoma						
Male	0.74	2	NC*	Male	10.01	11	110	
Female	78.31	62	79	Female	8.62	10	116	
Total	79.05	64	81	Total	18.64	21	113	
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx			
				Male	9.28	5	54	
Female	4.78	3	NC*	Female	3.97	2	NC*	
				Total	13.25	7	53	
Colon / Rectun	<u>1</u>		0	<u>vary</u>				
Male	37.40	34	91					
Female	32.26	28	87	Female	9.41	11	117	
Total	69.66	62	89					
<b>Esophagus</b>	agus Pancreas							
Male	4.77	6	126	Male	5.16	5	97	

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

Female	1.61	2	NC*	Female	5.16	3	NC*
Total	6.38	8	125	Total	10.32	8	78
Hodgkin's Di	<u>sease</u>		]	<u>Prostate</u>			
Male	1.91	3	NC*	Male	85.05	94	111
Female	1.53	3	NC*				
Total	3.44	6	175				
Kidney and R	enal Pelvis		<u>,</u>	Stomach_			
Male	8.10	8	99	Male	6.14	4	NC*
Female	4.68	3	NC*	Female	3.48	3	NC*
Total	12.78	11	86	Total	9.61	7	73
<b>Larynx</b>			r	<u> Festis</u>			
Male	5.14	7	136	Male	2.67	3	NC*
Female	1.37	2	NC*				
Total	6.51	9	138				
Leukemia			r	<u> Fhyroid</u>			
Male	5.37	6	112	Male	1.24	0	NC*
Female	3.85	1	NC*	Female	3.28	5	153
Total	9.22	7	76	Total	4.52	5	111
<b>Liver and Inti</b>	ahepatic Bi	le Ducts	1	U <mark>teri, Corp</mark> ı	us and Uter	us, NOS	
Male	2.29	1	NC*				
Female	0.98	0	NC*	Female	14.96	10	67
Total	3.27	1	NC*				
<b>Lung and Bro</b>	<u>nchus</u>		1	All Sites / T	ypes		
Male	46.24	53	115	Male	278.65	276	99
Female	31.09	34	109	Female	243.46	222	91
Total	77.33	87	113	Total	522.11	498	95

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

#### **AVON**

## Cancer Incidence by Sex, 1990 - 1995

	<b>Exp</b>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
<b>Bladder</b> , Urinary			$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>		
Male	3.68	4	NC*	Male	1.91	0	NC*
Female	1.36	1	NC*	Female	1.57	6	383 #+

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

Total	5.04	5	99	Total	3.48	6	172
<b>Brain and Cent</b>	ral Nervous	<u>System</u>	$\mathbf{M}$	lultiple Mye	eloma		
Male	1.28	4	NC*	Male	0.67	1	NC*
Female	1.21	1	NC*	Female	0.62	1	NC*
Total	2.49	5	201	Total	1.28	2	NC*
<b>Breast</b>			N	on-Hodgkin	's Lymphom	<u>a</u>	
Male	0.20	0	NC*	Male	2.74	2	NC*
Female	22.57	26	115	Female	2.45	2	NC*
Total	22.77	26	114	Total	5.19	4	NC*
Cervix Uteri			<u>o</u>	ral Cavity a	nd Pharynx		
				Male	2.57	1	NC*
Female	1.41	1	NC*	Female	1.14	1	NC*
				Total	3.71	2	NC*
Colon / Rectum	_		<u>o</u>	<u>vary</u>			
Male	9.79	9	92				
Female	9.00	13	144	Female	2.73	1	NC*
Total	18.79	22	117				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	1.29	2	NC*	Male	1.38	1	NC*
Female	0.45	0	NC*	Female	1.45	0	NC*
Total	1.74	2	NC*	Total	2.82	1	NC*
<b>Hodgkin's Dise</b>	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.57	0	NC*	Male	22.26	24	108
Female	0.45	1	NC*				
Total	1.02	1	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>comach</u>			
Male	2.20	2	NC*	Male	1.61	1	NC*
Female	1.34	1	NC*	Female	0.97	0	NC*
Total	3.54	3	NC*	Total	2.58	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.40	0	NC*	Male	0.81	1	NC*
Female	0.40	0	NC*				
Total	1.80	0	NC*				
<b>Leukemia</b>			<u>T</u>	<u>hyroid</u>			
Male	1.48	3	NC*	Male	0.36	1	NC*
Female	1.10	0	NC*	Female	0.97	5	513 ~+
Total	2.58	3	NC*	Total	1.33	6	450 ~+
<b>Liver and Intra</b>	hepatic Bile	<b>Ducts</b>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
Male	0.62	0	NC*				
Female	0.28	0	NC*	Female	4.31	1	NC*
Total	0.90	0	NC*				
<b>Lung and Brone</b>	<u>chu</u> s		<u>A</u>	ll Sites / Ty			
Male	12.35	15	121	Male	74.31	79	106
Female	8.87	15	169	Female	69.64	80	115
Total	21.22	30	141	Total	143.95	159	110

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

**Exp** 

~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<u>Obs</u>

^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

AYER

Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

<u>Obs</u>

<u>SIR</u>

Bladder, Urina	<u>ry</u>		$\mathbf{M}$	lelanoma of	<u>Skin</u>		
Male	3.39	3	NC*	Male	2.09	0	NC*
Female	1.61	2	NC*	Female	2.04	1	NC*
Total	5.00	5	100	Total	4.12	1	NC*
<b>Brain and Cen</b>	tral Nervous S	System	$\mathbf{M}$	Iultiple Mye	<u>loma</u>		
Male	1.54	1	NC*	Male	0.62	1	NC*
Female	1.55	0	NC*	Female	0.71	2	NC*
Total	3.09	1	NC*	Total	1.33	3	NC*
<b>Breast</b>				on-Hodgkin	s Lymphoma	1	
Male	0.19	0	NC*	Male	3.07	1	NC*
Female	26.77	19	71	Female	2.99	2	NC*
Total	26.96	19	70	Total	6.06	3	NC*
Cervix Uteri			<u>O</u>	ral Cavity a			
				Male	2.61	2	NC*
Female	1.97	4	NC*	Female	1.35	0	NC*
				Total	3.96	2	NC*
Colon / Rectun				<u>vary</u>			
Male	9.04	12	133				
Female	10.74	5	47	Female	3.33	3	NC*
Total	19.78	17	86				
<b>Esophagus</b>				ancreas			
Male	1.21	3	NC*	Male	1.30	1	NC*
Female	0.53	0	NC*	Female	1.68	5	298
Total	1.74	3	NC*	Total	2.98	6	201
<b>Hodgkin's Dis</b>				<u>rostate</u>			
Male	0.89	0	NC*	Male	19.95	24	120
Female	0.73	0	NC*				
Total	1.62	0	NC*				
Kidney and Re				<u>omach</u>			
Male	2.20	2	NC*	Male	1.52	1	NC*
Female	1.56	1	NC*	Female	1.19	3	NC*
Total	3.75	3	NC*	Total	2.71	4	NC*

<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.34	3	NC*	Male	1.45	3	NC*
Female	0.44	0	NC*				
Total	1.78	3	NC*				
<b>Leukemia</b>			<u>T</u> ]	<u>hyroid</u>			
Male	1.65	2	NC*	Male	0.49	0	NC*
Female	1.46	1	NC*	Female	1.43	3	NC*
Total	3.11	3	NC*	Total	1.92	3	NC*
<b>Liver and Int</b>	rahepatic Bile	Ducts	$\mathbf{U}_{1}$	teri, Corpus	s and Uterus,	NOS	
Male	0.61	1	NC*				
Female	0.33	0	NC*	Female	4.87	4	NC*
Total	0.94	1	NC*				
<b>Lung and Bro</b>	<u>onchus</u>		<u>A</u>	ll Sites / Ty	pes		
Male	11.54	16	139	Male	72.25	82	113
Female	9.77	12	123	Female	83.20	78	94
Total	21.32	28	131	Total	155.45	160	103
Male Female Total Liver and Int Male Female Total Lung and Bre Male Female	1.46 3.11 trahepatic Bile 0.61 0.33 0.94 tonchus 11.54 9.77	1 3 2 <b>Ducts</b> 1 0 1	NC* NC* NC* NC* NC* NC* NC* 139 123	Male Female Total teri, Corpus Female  Il Sites / Ty Male Female	1.43 1.92 <b>s and Uterus,</b> 4.87 <b>pes</b> 72.25 83.20	3 3 NOS 4 82 78	NC <sup>2</sup> NC <sup>2</sup> 111

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

#### **BARNSTABLE**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		M	lelanoma of	<u>Skin</u>		
Male	45.63	62	136 #+	Male	20.83	39	187 ^+
Female	16.17	12	74	Female	16.29	23	141
Total	61.81	74	120	Total	37.11	62	167 ^+
<b>Brain and Cen</b>	tral Nervous	<u>System</u>	M	lultiple Mye	<u>eloma</u>		
Male	13.21	19	144	Male	8.11	9	111
Female	12.75	17	133	Female	7.18	9	125
Total	25.97	36	139	Total	15.29	18	118
<b>Breast</b>			No	on-Hodgkin	<u>'s Lymphoma</u>		
Male	2.33	1	NC*	Male	30.39	24	79
Female	241.57	290	120 ~+	Female	27.84	27	97
Total	243.91	291	119 ~+	Total	58.23	51	88
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

				Male	27.55	27	98	
Female	14.03	17	121	Female	12.51	17	136	
				Total	40.07	44	110	
Colon / Rectun	<u>n</u>		0	<u>vary</u>				
Male	120.97	130	107					
Female	108.77	106	97	Female	28.65	28	98	
Total	229.74	236	103					
<b>Esophagus</b>			<u>Pa</u>	ancreas				
Male	14.72	19	129	Male	16.24	13	80	
Female	5.44	7	129	Female	17.09	20	117	
Total	20.16	26	129	Total	33.34	33	99	
<b>Hodgkin's Dis</b>	ease		<u>P</u> 1	<u>rostate</u>				
Male	5.22	3	NC*	Male	276.38	325	118 ~+	
Female	4.44	2	NC*					
Total	9.66	5	52					
Kidney and Re	enal Pelvis		<u>St</u>	omach				
Male	24.67	17	69	Male	19.80	13	66	
Female	14.71	18	122	Female	11.84	9	76	
Total	39.39	35	89	Total	31.65	22	70	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	15.58	20	128	Male	6.78	4	NC*	
Female	4.17	3	NC*					
Total	19.75	23	116					
<b>Leukemia</b>			$\mathbf{T}$	<u>hyroid</u>				
Male	16.57	21	127	Male	3.41	5	146	
Female	12.26	10	82	Female	9.53	10	105	
Total	28.83	31	108	Total	12.95	15	116	
Liver and Intra	ahepatic Bile	<b>Ducts</b>	$\underline{\mathbf{U}}$	teri, Corpus	s and Uterus,	<b>NOS</b>		
Male	7.08	5	71					
Female	3.21	4	NC*	Female	45.96	44	96	
Total	10.29	9	87					
<b>Lung and Bron</b>	<u>ichu</u> s		$\underline{\mathbf{A}}$	ll Sites / Ty	pes			
Male	144.69	155	107	Male	879.40	962	109 ~+	
Female	97.07	132	136 ^+	Female	768.90	849	110 ~+	
Total	241.76	287	119 ~+	Total	1648.30	1811	110 ^+	

Male

27.55

27

98

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

BARRE
Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinar	Y		$\mathbf{M}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	3.68	4	NC*	Male	1.85	5	271
Female	1.26	0	NC*	Female	1.42	1	NC*
Total	4.94	4	NC*	Total	3.26	6	184
<b>Brain and Cent</b>	ral Nervous	<u>System</u>	$\mathbf{M}$	Iultiple Mye	<u>loma</u>		
Male	1.25	2	NC*	Male	0.66	0	NC*
Female	1.12	0	NC*	Female	0.57	0	NC*
Total	2.37	2	NC*	Total	1.23	0	NC*
<b>Breast</b>			N	on-Hodgkin	s Lymphoma	<u>a</u>	
Male	0.19	0	NC*	Male	2.69	0	NC*
Female	20.10	15	75	Female	2.26	4	NC*
Total	20.29	15	74	Total	4.95	4	NC*
Cervix Uteri			<u>o</u>	ral Cavity a	nd Pharynx		
				Male	2.43	0	NC*
Female	1.28	0	NC*	Female	1.02	1	NC*
				Total	3.45	1	NC*
Colon / Rectum	ı		<u>o</u>	<u>vary</u>			
Male	9.79	9	92				
Female	8.41	9	107	Female	2.44	4	NC*
Total	18.21	18	99				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	1.24	0	NC*	Male	1.35	3	NC*
Female	0.42	0	NC*	Female	1.34	3	NC*
Total	1.66	0	NC*	Total	2.69	6	223
<b>Hodgkin's Dise</b>	ase		<u>P</u> 1	<u>rostate</u>			
Male	0.57	1	NC*	Male	22.22	17	76
Female	0.45	3	NC*				
Total	1.01	4	NC*				
Kidney and Rei	nal Pelvis		<u>St</u>	tomach_			
Male	2.13	4	NC*	Male	1.61	3	NC*
Female	1.21	1	NC*	Female	0.91	2	NC*
Total	3.35	5	149	Total	2.52	5	198
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.34	0	NC*	Male	0.79	0	NC*
Female	0.34	1	NC*				
Total	1.68	1	NC*				
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>			
Male	1.48	1	NC*	Male	0.34	0	NC*
Female	1.06	1	NC*	Female	0.90	1	NC*
Total	2.54	2	NC*	Total	1.25	1	NC*
<b>Liver and Intra</b>	hepatic Bile	<u>Ducts</u>	<u>U</u>	teri, Corpus	and Uterus,	<u>NOS</u>	

Male	0.60	0	NC*				
Female	0.26	0	NC*	Female	3.79	3	NC*
Total	0.86	0	NC*				
<b>Lung and Bro</b>	nchus		<u>A</u> ]	ll Sites / Ty	pes		
Male	12.07	6	50	Male	73.45	66	90
Female	7.90	1	NC*	Female	63.09	51	81
Total	19.97	7	35 ~-	Total	136.54	117	86

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## BECKET Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	Obs	<u>SIR</u>
Bladder, Urinary			<u>M</u>	lelanoma of	<u>Skin</u>		
Male	1.20	0	NC*	Male	0.63	0	NC*
Female	0.34	0	NC*	Female	0.44	0	NC*
Total	1.54	0	NC*	Total	1.07	0	NC*
<b>Brain and Central</b>	Nervou	s System	$\mathbf{M}$	lultiple Mye	<u>loma</u>		
Male	0.43	1	NC*	Male	0.22	0	NC*
Female	0.34	0	NC*	Female	0.16	0	NC*
Total	0.77	1	NC*	Total	0.37	0	NC*
<b>Breast</b>			No	on-Hodgkin'	's Lymphom	<u>a</u>	
Male	0.06	0	NC*	Male	0.92	1	NC*
Female	5.99	7	117	Female	0.64	1	NC*
Total	6.06	7	116	Total	1.56	2	NC*
Cervix Uteri			<u>O</u> :	ral Cavity aı	nd Pharynx		
				Male	0.84	0	NC*
Female	0.42	0	NC*	Female	0.30	0	NC*
				Total	1.14	0	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	3.19	3	NC*				
Female	2.23	4	NC*	Female	0.74	0	NC*
Total	5.42	7	129				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	0.42	0	NC*	Male	0.45	0	NC*

0.53	0	NC*	Total	0.81	1	NC*
ase		<u>P</u> 1	<u>rostate</u>			
0.20	0	NC*	Male	7.22	1	NC*
0.15	1	NC*				
0.35	1	NC*				
al Pelvis		St	<u>omach</u>			
0.73	0	NC*	Male	0.52	0	NC*
0.35	0	NC*	Female	0.24	0	NC*
1.08	0	NC*	Total	0.76	0	NC*
		<u>T</u>	<u>estis</u>			
0.46	0	NC*	Male	0.29	0	NC*
0.10	0	NC*				
0.56	0	NC*				
		<u>T</u>	nyroid			
0.50	0	NC*	Male	0.12	0	NC*
0.30	0	NC*	Female	0.30	0	NC*
0.80	0	NC*	Total	0.42	0	NC*
nepatic Bile D	<u>ucts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
0.20	0	NC*				
0.07	0	NC*	Female	1.13	0	NC*
0.27	0	NC*				
<u>hu</u> s		$\mathbf{A}$	ll Sites / Typ	<u>oes</u>		
4.04	1	NC*	Male	24.38	8	33 ^-
2.29	1	NC*	Female	18.28	16	88
		NC*	Total	42.66	24	56 ~-
	0.20 0.15 0.35 1 Pelvis 0.73 0.35 1.08 0.46 0.10 0.56 0.50 0.30 0.80 1 Pelvis 0.20 0.20 0.07 0.27 1 Pelvis 1 Pelvis	0.20 0 0.15 1 0.35 1  1al Pelvis 0.73 0 0.35 0 1.08 0 0.46 0 0.10 0 0.56 0 0.50 0 0.30 0 0.80 0 0.80 0 0.90 0 0.27 0 0.27 0 0.40 0 0.40 0 0.27 0 0.40 0 0.50 0 0.50 0 0.80	Dase   Process   Process	Depart   D	Prostate	NC   NC   Male   7.22   1

NC\*

Female

0.36

NC\*

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

Female

0.11

0

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases

- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **BEDFORD**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	y		$\mathbf{M}$	Ielanoma of	<u>Skin</u>		
Male	13.24	13	98	Male	6.58	4	NC*
Female	3.52	1	NC*	Female	3.98	2	NC*

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

Total	16.76	14	84	Total	10.56	6	57
<b>Brain and Cent</b>	tral Nervous	<u>System</u>	$\mathbf{M}$	lultiple My	eloma		
Male	4.21	5	119	Male	2.39	5	209
Female	3.02	8	265 #+	Female	1.57	3	NC*
Total	7.22	13	180	Total	3.96	8	202
<b>Breast</b>			N	on-Hodgkin	's Lymphon	<u>1a</u>	
Male	0.70	0	NC*	Male	9.42	7	74
Female	57.44	70	122	Female	6.22	6	96
Total	58.13	70	120	Total	15.64	13	83
Cervix Uteri			<u>o</u>	ral Cavity a	nd Pharynx		
				Male	8.82	6	68
Female	3.55	3	NC*	Female	2.91	3	NC*
				Total	11.74	9	77
Colon / Rectum	<u>1</u>		<u>o</u>	<u>vary</u>			
Male	35.19	26	74				
Female	23.33	27	116	Female	6.92	7	101
Total	58.52	53	91				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	4.52	4	NC*	Male	4.86	1	NC*
Female	1.16	1	NC*	Female	3.68	7	190
Total	5.68	5	88	Total	8.54	8	94
<b>Hodgkin's Disc</b>	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.76	0	NC*	Male	79.80	66	83
Female	1.09	0	NC*				
Total	2.86	0	NC*				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	7.64	6	79	Male	5.78	5	86
Female	3.32	4	NC*	Female	2.57	2	NC*
Total	10.96	10	91	Total	8.35	7	84
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	4.88	1	NC*	Male	2.48	1	NC*
Female	1.00	1	NC*				
Total	5.87	2	NC*				
<b>Leukemia</b>				<u>hyroid</u>			
Male	4.99	4	NC*	Male	1.17	1	NC*
Female	2.80	5	178	Female	2.43	6	247
Total	7.79	9	116	Total	3.60	7	195
Liver and Intra	ahepatic Bile			teri, Corpus	s and Uterus	s, NOS	
Male	2.15	2	NC*				
Female	0.70	0	NC*	Female	10.85	14	129
Total	2.85	2	NC*				
<b>Lung and Bron</b>				ll Sites / Ty			
Male	43.60	32	73	Male	262.05	205	78 ^-
Female	21.69	21	97	Female	176.56	202	114
Total	65.29	53	81	Total	438.61	407	93

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## **BELCHERTOWN**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>iry</u>		$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>		
Male	7.00	5	71	Male	3.92	0	NC*
Female	2.38	2	NC*	Female	3.23	3	NC*
Total	9.37	7	75	Total	7.15	3	NC*
<b>Brain and Cen</b>	tral Nervous	s System	$\mathbf{M}$	<b>Jultiple Mye</b>	eloma		
Male	2.73	2	NC*	Male	1.27	5	392 #+
Female	2.45	3	NC*	Female	1.07	1	NC*
Total	5.18	5	97	Total	2.35	6	255
<b>Breast</b>			No	on-Hodgkin	's Lymphoma	<u>a</u>	
Male	0.38	0	NC*	Male	5.67	2	NC*
Female	42.36	35	83	Female	4.55	2	NC*
Total	42.75	35	82	Total	10.21	4	NC*
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	5.08	6	118
Female	3.18	4	NC*	Female	2.09	1	NC*
				Total	7.17	7	98
Colon / Rectur	<u>n</u>		<u>O</u>	<u>vary</u>			
Male	18.59	14	75				
Female	15.68	15	96	Female	5.32	4	NC*
Total	34.27	29	85				
<b>Esophagus</b>			Pa	ancreas			
Male	2.46	2	NC*	Male	2.63	1	NC*
Female	0.77	0	NC*	Female	2.50	4	NC*
Total	3.24	2	NC*	Total	5.13	5	97
<b>Hodgkin's Dis</b>	<u>sease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.39	2	NC*	Male	41.12	33	80
Female	1.16	1	NC*				
Total	2.55	3	NC*				
Kidney and R	enal Pelvis		St	omach			
Male	4.31	1	NC*	Male	3.10	5	161
Female	2.43	3	NC*	Female	1.72	3	NC*
Total	6.74	4	NC*	Total	4.81	8	166

<b>Larynx</b>			<u>T</u>	<u>estis</u>			
Male	2.69	2	NC*	Male	2.15	3	NC*
Female	0.70	1	NC*				
Total	3.39	3	NC*				
Leukemia			<u>T</u>	hyroid			
Male	3.05	1	NC*	Male	0.82	1	NC*
Female	2.23	3	NC*	Female	2.30	0	NC*
Total	5.28	4	NC*	Total	3.12	1	NC*
Liver and Intr	ahepatic Bile D	<u>ucts</u>	$\underline{\mathbf{U}}_1$	teri, Corpus	s and Uterus,	NOS	
Liver and Intr Male	rahepatic Bile D 1.20	<u>Oucts</u> 0	NC*	teri, Corpus	s and Uterus,	<u>NOS</u>	
	•			<b>teri, Corpus</b> Female	s and Uterus, 7.77	<b>NOS</b> 7	90
Male	1.20	0	NC*	-			90
Male Female	1.20 0.50 1.70	0 0	NC* NC* NC*	-	7.77		90
Male Female Total	1.20 0.50 1.70	0 0	NC* NC* NC*	Female	7.77		90 87
Male Female Total Lung and Bro	1.20 0.50 1.70 <b>nchus</b>	0 0 0	NC* NC* NC*	Female	7.77 <b>pes</b>	7	
Male Female Total Lung and Bro	1.20 0.50 1.70 nchus 23.37	0 0 0 28	NC* NC* NC* <u>Al</u> 120	Female  Il Sites / Ty  Male	7.77  pes  143.38	7	87

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

#### **BELLINGHAM**

## Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urinary			Melanoma of Skin					
Male	8.27	16	193 #+	Male	5.08	6	118	
Female	2.92	7	240	Female	4.31	4	NC*	
Total	11.19	23	206 ~+	Total	9.39	10	106	
<b>Brain and Central Nervous System</b>			Multiple Myeloma					
Male	3.62	2	NC*	Male	1.53	0	NC*	
Female	3.23	3	NC*	Female	1.35	2	NC*	
Total	6.85	5	73	Total	2.89	2	NC*	
<b>Breast</b>	Non-Hodgkin's Lymphoma							
Male	0.47	0	NC*	Male	7.25	8	110	
Female	56.61	65	115	Female	5.74	5	87	
Total	57.07	65	114	Total	12.99	13	100	
Cervix Uteri	Oral Cavity and Pharynx							

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

				Male	6.72	6	89		
Female	4.27	4	NC*	Female	2.77	1	NC*		
				Total	9.49	7	74		
Colon / Rectum Ovary									
Male	22.11	25	113						
Female	18.84	17	90	Female	7.14	11	154		
Total	40.96	42	103						
<b>Esophagus</b> Pancreas									
Male	3.13	4	NC*	Male	3.26	5	153		
Female	0.94	2	NC*	Female	3.08	1	NC*		
Total	4.07	6	147	Total	6.35	6	95		
Hodgkin's Disease Prostate									
Male	1.90	1	NC*	Male	49.47	51	103		
Female	1.51	1	NC*						
Total	3.40	2	NC*						
Kidney and Renal Pelvis Stomach									
Male	5.55	4	NC*	Male	3.68	1	NC*		
Female	3.18	5	157	Female	2.03	0	NC*		
Total	8.73	9	103	Total	5.71	1	NC*		
<b>Larynx</b>			<u>T</u>	<u>estis</u>					
Male	3.51	4	NC*	Male	3.01	4	NC*		
Female	0.98	1	NC*						
Total	4.48	5	112						
<u>Leukemia</u> <u>Thyroid</u>									
Male	3.84	1	NC*	Male	1.12	0	NC*		
Female	2.79	2	NC*	Female	3.07	3	NC*		
Total	6.63	3	NC*	Total	4.19	3	NC*		
<b>Liver and Intra</b>	<b>Uteri, Corpus and Uterus, NOS</b>								
Male	1.52	0	NC*						
Female	0.63	0	NC*	Female	10.55	17	161		
Total	2.15	0	NC*						
<u>Lung and Bronchus</u> <u>All Sites / Types</u>									
Male	29.42	27	92	Male	177.55	171	96		
Female	20.54	10	49 #-	Female	167.96	168	100		
Total	49.96	37	74	Total	345.51	339	98		

Male

672

29

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# BELMONT Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	Obs	SIR
Bladder, Urinary Melanoma of Skin							
Male	22.72	22	97	Male	10.85	9	83
Female	9.09	13	143	Female	9.49	14	148
Total	31.81	35	110	Total	20.33	23	113
<b>Brain and Central Nervous System</b>				<u> [ultiple Myc</u>			
Male	6.85	8	117	Male	4.05	3	NC*
Female	7.19	6	83	Female	4.00	1	NC*
Total	14.04	14	100	Total	8.05	4	NC*
<b>Breast</b>			Non-Hodgkin's Lymphoma				
Male	1.18	1	NC*	Male	15.67	9	57
Female	136.77	166	121 #+	Female	15.75	17	108
Total	137.95	167	121 #+	Total	31.41	26	83
Cervix Uteri			Oral Cavity and Pharynx				
				Male	14.20	8	56
Female	8.36	4	NC*	Female	7.01	8	114
				Total	21.21	16	75
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	59.92	60	100				
Female	61.52	55	89	Female	16.33	17	104
Total	121.44	115	95				
<b>Esophagus</b>			Pa	<u>ancreas</u>			
Male	7.41	5	67	Male	8.04	6	75
Female	3.03	1	NC*	Female	9.54	11	115
Total	10.44	6	57	Total	17.57	17	97
Hodgkin's Dis	<u>P</u> 1	<u>rostate</u>					
Male	2.90	8	276 #+	Male	131.73	188	143 ^+
Female	2.69	2	NC*				
Total	5.59	10	179				
Kidney and Renal Pelvis			Stomach				
Male	12.37	8	65	Male	9.97	14	140
Female	8.12	5	62	Female	6.81	2	NC*
Total	20.49	13	63	Total	16.78	16	95
Larynx	Testis						
Male	7.81	6	77	Male	4.05	5	124
Female	2.27	0	NC*				
Total	10.08	6	60				
Leukemia							
Male	8.39	12	143	Male	1.87	6	321 #+
Female	7.00	12	171	Female	5.76	8	139
Total	15.38	24	156	Total	7.63	14	184 #+
Liver and Intrahepatic Bile Ducts			<b>Uteri, Corpus and Uterus, NOS</b>				

Male	3.53	4	NC*				
Female	1.78	4	NC*	Female	25.46	20	79
Total	5.31	8	151				
<b>Lung and Bron</b>	<u>ichus</u>	All Sites / Types					
Male	70.77	49	69 ~-	Male	434.41	460	106
Female	52.70	51	97	Female	433.27	465	107

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **BERKLEY**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	Obs	<u>SIR</u>		
Bladder, Urinary	,		$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>				
Male	2.08	3	NC*	Male	1.36	1	NC*		
Female	0.70	0	NC*	Female	1.15	1	NC*		
Total	2.78	3	NC*	Total	2.50	2	NC*		
<b>Brain and Centra</b>	al Nervou	s System	$\underline{\mathbf{M}}$	lultiple Mye	<u>loma</u>				
Male	1.01	0	NC*	Male	0.39	1	NC*		
Female	0.87	0	NC*	Female	0.32	0	NC*		
Total	1.89	0	NC*	Total	0.71	1	NC*		
<b>Breast</b>	Non-Hodgkin's Lymphoma								
Male	0.12	0	NC*	Male	1.95	1	NC*		
Female	14.16	15	106	Female	1.43	0	NC*		
Total	14.28	15	105	Total	3.38	1	NC*		
Cervix Uteri			<u>O</u>	ral Cavity ar	nd Pharynx				
				Male	1.75	2	NC*		
Female	1.19	1	NC*	Female	0.69	1	NC*		
				Total	2.44	3	NC*		
Colon / Rectum			0	<u>vary</u>					
Male	5.53	4	NC*						
Female	4.46	5	112	Female	1.84	0	NC*		
Total	10.00	9	90						
<b>Esophagus</b>			<u>Pa</u>	ancreas					
Male	0.79	2	NC*	Male	0.82	0	NC*		

.01 2 .57 0 .46 2 .03 2  elvis .43 2 .78 1 .21 3 .89 0 .23 0 .12 0	NC* NC* NC* NC* NC* NC*	Prostate Male  Stomach Male Female Total Testis Male  Thyroid	1.54 11.81 0.94 0.49 1.43	2 15 0 0 0	NC* 127  NC* NC* NC*
.46 2 .03 2 .48 2 .43 2 .78 1 .21 3 .89 0 .23 0 .12 0	NC* NC* NC* NC* NC* NC*	Male  Stomach  Male Female Total  Testis  Male	0.94 0.49 1.43	0 0 0	NC* NC* NC*
.46 2 .03 2 .48 2 .43 2 .78 1 .21 3 .89 0 .23 0 .12 0	NC* NC* NC* NC* NC* NC*	Stomach  Male Female Total Testis Male	0.94 0.49 1.43	0 0 0	NC* NC* NC*
.03 2 elvis .43 2 .78 1 .21 3 .89 0 .23 0 .12 0	NC* NC* NC* NC* NC*	Stomach Male Female Total Testis Male Thyroid	0.49 1.43	0	NC* NC*
Elvis         .43       2         .78       1         .21       3         .89       0         .23       0         .12       0	NC* NC* NC* NC*	Stomach  Male Female Total Testis Male  Thyroid	0.49 1.43	0	NC* NC*
.43 2 .78 1 .21 3 .89 0 .23 0 .12 0	NC* NC* NC* NC*	Male Female Total Testis Male Thyroid	0.49 1.43	0	NC* NC*
.78 1 .21 3 .89 0 .23 0 .12 0	NC* NC* NC* NC*	Female Total Testis Male Thyroid	0.49 1.43	0	NC* NC*
.21 3 .89 0 .23 0 .12 0	NC* NC* NC*	Total Testis Male Thyroid	1.43	0	NC*
.89 0 .23 0 .12 0	NC* NC*	Testis Male Thyroid			
.23 0 .12 0	NC*	Male Thyroid	0.90	0	NC*
.23 0 .12 0	NC*	<u>Thyroid</u>	0.90	0	NC*
.12 0	NC*	<u>Thyroid</u>			
		<b>Thyroid</b>			
06 0	NOV				
06	NICH				
.00	NC*	Male	0.32	1	NC*
.77 0	NC*	Female	0.88	1	NC*
.83 0	NC*	Total	1.20	2	NC*
ic Bile Ducts		Uteri, Corp	us and Uter	us, NOS	
.39 0	NC*				
.16 0	NC*	Female	2.56	0	NC*
.54 0	NC*	:			
		All Sites / T	<u> Types</u>		
.28 11	151	Male	44.89	45	100
.83 8	166	Female	41.81	39	93
.11 19	157	Total	86.70	84	97
,	.16 0 .54 0 .28 11 .83 8	0.16 0 NC* 0.54 0 NC* 0.28 11 151 0.83 8 166	.16 0 NC* Female .54 0 NC*  All Sites / T .28 11 151 Male .83 8 166 Female	.16 0 NC* Female 2.56 .54 0 NC*  All Sites / Types  .28 11 151 Male 44.89  .83 8 166 Female 41.81	.16 0 NC* Female 2.56 0 .54 0 NC*  All Sites / Types .28 11 151 Male 44.89 45 .83 8 166 Female 41.81 39

NC\*

Female

0.72

2

NC\*

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

Female

0.22

0

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **BERLIN**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	<b>Obs</b>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
<b>Bladder</b> , Urinary		Melanoma of Skin							
Male	1.90	3	NC*	Male	1.00	0	NC*		
Female	0.54	0	NC*	Female	0.70	0	NC*		

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

Total	2.44	3	NC*	Total	1.70	0	NC*
<b>Brain and Cent</b>	ral Nervous S	ystem	$\mathbf{M}$	lultiple Mye	loma		
Male	0.66	0	NC*	Male	0.34	0	NC*
Female	0.53	0	NC*	Female	0.25	0	NC*
Total	1.19	0	NC*	Total	0.59	0	NC*
<b>Breast</b>			N	on-Hodgkin'	s Lymphoma	ì	
Male	0.10	0	NC*	Male	1.41	1	NC*
Female	9.64	5	52	Female	1.01	1	NC*
Total	9.74	5	51	Total	2.43	2	NC*
Cervix Uteri			<u>o</u>	ral Cavity aı	nd Pharynx		
				Male	1.35	1	NC*
Female	0.66	0	NC*	Female	0.48	1	NC*
				Total	1.83	2	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	5.02	1	NC*				
Female	3.56	3	NC*	Female	1.19	1	NC*
Total	8.58	4	NC*				
<b>Esophagus</b>			Pa	ancreas			
Male	0.67	0	NC*	Male	0.70	1	NC*
Female	0.18	0	NC*	Female	0.58	1	NC*
Total	0.85	0	NC*	Total	1.28	2	NC*
<b>Hodgkin's Dise</b>	<u>ase</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.29	0	NC*	Male	11.09	6	54
Female	0.22	0	NC*				
Total	0.51	0	NC*				
Kidney and Rer	<u>ıal Pelvis</u>		St	omach			
Male	1.13	1	NC*	Male	0.84	1	NC*
Female	0.56	0	NC*	Female	0.38	1	NC*
Total	1.69	1	NC*	Total	1.22	2	NC*
<b>Larynx</b>			<u>T</u>	<u>estis</u>			
Male	0.73	0	NC*	Male	0.41	0	NC*
Female	0.17	0	NC*				
Total	0.90	0	NC*				
<b>Leukemia</b>			<u>T</u>	<u>hyroid</u>			
Male	0.76	0	NC*	Male	0.18	0	NC*
Female	0.47	0	NC*	Female	0.46	0	NC*
Total	1.23	0	NC*	Total	0.65	0	NC*
Liver and Intral	<u>hepatic Bile D</u>	<u>Oucts</u>		teri, Corpus	and Uterus,	NOS	
Male	0.32	0	NC*				
Female	0.11	1	NC*	Female	1.82	0	NC*
Total	0.43	1	NC*				
<b>Lung and Brond</b>				ll Sites / Typ	<u>oes</u>		
Male	6.26	4	NC*	Male	37.81	20	53 ~-
Female	3.65	3	NC*	Female	29.21	19	65
Total	9.91	7	71	Total	67.02	39	58 ^-

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **BERNARDSTON**

#### Cancer Incidence by Sex, 1990 - 1995

Bladder, Urinary Melanoma of Skin	Mak								
Male 1.72 2 NC* Male 0.85 1	NC*								
Female 0.61 1 NC* Female 0.67 1	NC*								
Total 2.34 3 NC* Total 1.52 2	NC*								
Brain and Central Nervous System Multiple Myeloma									
Male 0.57 0 NC* Male 0.31 0	NC*								
Female 0.52 0 NC* Female 0.27 2	NC*								
Total 1.09 0 NC* Total 0.58 2	NC*								
Breast Non-Hodgkin's Lymphoma									
Male 0.09 0 NC* Male 1.24 2	NC*								
Female 9.66 12 124 Female 1.09 1	NC*								
Total 9.75 12 123 Total 2.32 3	NC*								
Cervix Uteri Oral Cavity and Pharynx									
Male 1.14 2	NC*								
Female 0.60 1 NC* Female 0.49 1	NC*								
Total 1.63 3	NC*								
Colon / Rectum Ovary									
Male 4.59 4 NC*									
Female 4.13 3 NC* Female 1.16 2	NC*								
Total 8.72 7 80									
<b>Esophagus</b> Pancreas									
Male 0.58 1 NC* Male 0.63 0	NC*								
Female 0.20 0 NC* Female 0.65 0	NC*								
Total 0.79 1 NC* Total 1.29 0	NC*								
Hodgkin's Disease Prostate									
Male 0.25 0 NC* Male 10.56 9	85								
Female 0.20 0 NC*									
Total 0.44 0 NC*									
Kidney and Renal Pelvis Stomach									
Male 1.00 1 NC* Male 0.75 0	NC*								
Female 0.58 1 NC* Female 0.45 1	NC*								
Total 1.58 2 NC* Total 1.20 1	NC*								

Larynx			<u>T</u>	<u>estis</u>			
Male	0.63	1	NC*	Male	0.34	1	NC*
Female	0.16	0	NC*				
Total	0.79	1	NC*				
Leukemia			<u>T</u> ]	<u>hyroid</u>			
Male	0.68	2	NC*	Male	0.15	0	NC*
Female	0.50	0	NC*	Female	0.41	0	NC*
Total	1.18	2	NC*	Total	0.57	0	NC*
		ic Bile Ducts Uteri, Corpus and Uterus, NOS					
<b>Liver and Intra</b>	ahepatic Bile D	<u>ucts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	<u>NOS</u>	
Liver and Intra Male	hepatic Bile D 0.28	<u>ucts</u> 0	NC*	<u>teri, Corpus</u>	and Uterus,	<u>NOS</u>	
				teri, Corpus Female	and Uterus,	<b>NOS</b> 1	NC*
Male	0.28	0	NC*				NC*
Male Female	0.28 0.12 0.41	0	NC* NC* NC*		1.82		NC*
Male Female Total	0.28 0.12 0.41	0	NC* NC* NC*	Female	1.82		NC*
Male Female Total Lung and Bron	0.28 0.12 0.41 chus	0 0 0	NC* NC* NC*	Female	1.82 <b>Des</b>	1	
Male Female Total Lung and Bron Male	0.28 0.12 0.41 chus 5.71	0 0 0 7	NC* NC* NC* 123	Female  Il Sites / Typ  Male	1.82 Des 34.44	1 36	105

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

## **BEVERLY**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	<u>Obs</u>	SIR			
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>					
Male	29.33	28	95	Male	15.00	19	127			
Female	12.31	10	81	Female	13.25	19	143			
Total	41.63	38	91	Total	28.25	38	135			
<b>Brain and Cen</b>	tral Nervous System Multiple Myeloma									
Male	9.92	13	131	Male	5.29	4	NC*			
Female	10.19	13	128	Female	5.43	3	NC*			
Total	20.12	26	129	Total	10.72	7	65			
<b>Breast</b>			No	on-Hodgkin	's Lymphoma					
Male	1.56	4	NC*	Male	21.66	28	129			
Female	187.99	202	107	Female	21.60	20	93			
Total	189.55	206	109	Total	43.26	48	111			
Cervix Uteri	Oral Cavity and Pharynx									

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

				Male	19.73	27	137				
Female	11.88	9	76	Female	9.63	10	104				
				Total	29.36	37	126				
Colon / Rectu	ım		(	Ovary							
Male	77.84	95	122								
Female	82.95	93	112	Female	22.64	17	75				
Total	160.79	188	117 #+								
<b>Esophagus</b>			<u> </u>	<u>Pancreas</u>							
Male	9.97	5	50	Male	10.76	6	56				
Female	4.10	4	NC*	Female	12.92	12	93				
Total	14.07	9	64	Total	23.68	18	76				
Hodgkin's D	<u>isease</u>		<u> </u>	<u>Prostate</u>							
Male	4.53	7	154	Male	174.62	168	96				
Female	4.00	7	175								
Total	8.54	14	164								
Kidney and Renal Pelvis Stomach											
Male	17.04	13	76	Male	12.87	12	93				
Female	11.23	18	160	Female	9.14	5	55				
Total	28.27	31	110	Total	22.01	17	77				
<u>Larynx</u>			<u>1</u>	<u>Cestis</u>							
Male	10.75	14	130	Male	6.63	5	75				
Female	3.13	2	NC*								
Total	13.88	16	115								
<b>Leukemia</b>			<u>1</u>	<b>Thyroid</b>							
Male	11.61	18	155	Male	2.82	1	NC*				
Female	9.86	8	81	Female	8.30	5	60				
Total	21.47	26	121	Total	11.12	6	54				
<b>Liver and Int</b>			_	I <mark>teri, Corp</mark> u	is and Uterus	s, NOS					
Male	4.80	7	146								
Female	2.45	3	NC*	Female	34.98	34	97				
Total	7.25	10	138								
Lung and Bro			_	All Sites / T							
Male	95.86	90	94	Male	583.48	607	104				
Female	72.49	89	123	Female	595.15	631	106				
Total	168.34	179	106	Total	1178.63	1238	105				

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **BILLERICA**

# Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	Obs	SIR	
Bladder, Urina				lelanoma of				
Male	18.48	16	87	Male	12.05	10	83	
Female	6.37	2	NC*	Female	9.69	10	103	
Total	24.84	18	72	Total	21.74	20	92	
<b>Brain and Cen</b>				<u>lultiple My</u>				
Male	8.65	7	81	Male	3.45	4	NC*	
Female	7.20	9	125	Female	2.94	5	170	
Total	15.85	16	101	Total	6.39	9	141	
<b>Breast</b>					<u>'s Lymphom</u>	<u>a</u>		
Male	1.07	0	NC*	Male	17.06	18	105	
Female	125.97	145	115	Female	12.60	12	95	
Total	127.03	145	114	Total	29.66	30	101	
Cervix Uteri			<u>O</u>	ral Cavity a	<u>nd Pharynx</u>			
				Male	15.80	18	114	
Female	9.64	11	114	Female	6.13	5	82	
				Total	21.93	23	105	
Colon / Rectun	<u>Ovary</u>							
Male	49.22	59	120					
Female	40.99	36	88	Female	15.96	13	81	
Total	90.21	95	105					
<b>Esophagus</b>			<u>Pa</u>	ancreas				
Male	7.16	5	70	Male	7.33	7	95	
Female	2.03	2	NC*	Female	6.64	6	90	
Total	9.19	7	76	Total	13.98	13	93	
<b>Hodgkin's Dis</b>	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	4.74	4	NC*	Male	105.85	82	77 #-	
Female	3.39	3	NC*					
Total	8.13	7	86					
Kidney and Re	enal Pelvis		St	omach_				
Male	12.75	7	55	Male	8.33	8	96	
Female	6.92	12	173	Female	4.49	5	111	
Total	19.67	19	97	Total	12.82	13	101	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	8.05	10	124	Male	7.68	4	NC*	
Female	2.15	3	NC*					
Total	10.20	13	127					
<b>Leukemia</b>			<u>T</u>	<u>hyroid</u>				
Male	8.98	18	200 #+	Male	2.76	1	NC*	
Female	6.26	4	NC*	Female	6.96	4	NC*	
Total	15.24	22	144	Total	9.72	5	51	
<b>Liver and Intra</b>	ahepatic Bile	<u>Ducts</u>	<u>U</u> :	teri, Corpus	s and Uterus,	NOS		

Male	3.46	1	NC*						
Female	1.36	4	NC*	Female	23.27	25	107		
Total	4.82	5	104						
<b>Lung and Bro</b>	ung and Bronchus Al				ll Sites / Types				
Male	65.52	65	99	Male	398.82	379	95		
Female	44.07	80	182 ^+	Female	370.42	424	114 ~+		
Total	109.59	145	132 ~+	Total	769.24	803	104		

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **BLACKSTONE**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	<u>SIR</u>		Exp	Obs	SIR		
Bladder, Urinar	<b>y</b>		<u>M</u>	lelanoma of	<u>Skin</u>				
Male	5.04	4	NC*	Male	2.91	2	NC*		
Female	1.93	0	NC*	Female	2.47	3	NC*		
Total	6.98	4	NC*	Total	5.39	5	93		
<b>Brain and Cent</b>	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>oma</u>				
Male	2.07	3	NC*	Male	0.92	1	NC*		
Female	1.90	0	NC*	Female	0.87	2	NC*		
Total	3.97	3	NC*	Total	1.79	3	NC*		
<b>Breast</b>		Non-Hodgkin's Lymphoma							
Male	0.28	1	NC*	Male	4.24	3	NC*		
Female	32.94	26	79	Female	3.61	2	NC*		
Total	33.21	27	81	Total	7.85	5	64		
Cervix Uteri			<u>O</u> :	ral Cavity ar	d Pharynx				
				Male	3.73	1	NC*		
Female	2.38	1	NC*	Female	1.65	1	NC*		
				Total	5.38	2	NC*		
Colon / Rectum			<u>O</u>	<u>vary</u>					
Male	13.42	10	75						
Female	12.79	13	102	Female	4.10	3	NC*		
Total	26.20	23	88						
<b>Esophagus</b>			<u>Pa</u>	ancreas					
Male	1.78	2	NC*	Male	1.91	1	NC*		

1 Ciliaic	0.03	1	NC	Temate	2.03	U	NC
Total	2.42	3	NC*	Total	3.94	1	NC*
Hodgkin's Dise	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.11	4	NC*	Male	29.77	21	71
Female	0.87	1	NC*				
Total	1.98	5	253				
Kidney and Re	nal Pelvis		St	omach			
Male	3.16	7	222	Male	2.24	0	NC*
Female	1.92	2	NC*	Female	1.40	1	NC*
Total	5.08	9	177	Total	3.64	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.96	3	NC*	Male	1.75	3	NC*
Female	0.55	1	NC*				
Total	2.51	4	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	2.28	2	NC*	Male	0.63	0	NC*
Female	1.75	2	NC*	Female	1.72	0	NC*
Total	4.03	4	NC*	Total	2.35	0	NC*
<b>Liver and Intra</b>	hepatic Bile I	<u>Oucts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
Male	0.88	1	NC*				
Female	0.40	0	NC*	Female	6.08	3	NC*
Total	1.28	1	NC*				
<b>Lung and Bron</b>	<u>chu</u> s		<u>A</u>	ll Sites / Ty	pes		
Male	16.96	11	65	Male	104.81	88	84
Female	12.25	10	82	Female	101.60	80	79 #-
Total	29.22	21	72	Total	206.41	168	81 ~-
-							

NC\*

Female

2.03

0

NC\*

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

Female

0.63

1

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **BLANDFORD**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<b>SIR</b>
<b>Bladder</b> , Urinary			$\mathbf{M}$	lelanoma of S	<u>Skin</u>		
Male	0.89	0	NC*	Male	0.50	0	NC*
Female	0.23	0	NC*	Female	0.34	1	NC*

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

Total	1.12	0	NC*	Total	0.84	1	NC*
<b>Brain and Centi</b>	ral Nervous S	<u>ystem</u>	$\mathbf{M}$	Iultiple Mye	<u>loma</u>		
Male	0.34	0	NC*	Male	0.16	0	NC*
Female	0.26	0	NC*	Female	0.11	0	NC*
Total	0.60	0	NC*	Total	0.27	0	NC*
<b>Breast</b>			No	on-Hodgkin'	s Lymphoma	1	
Male	0.05	0	NC*	Male	0.70	2	NC*
Female	4.51	4	NC*	Female	0.46	0	NC*
Total	4.56	4	NC*	Total	1.16	2	NC*
Cervix Uteri			<u>O</u>	ral Cavity aı	nd Pharynx		
				Male	0.70	1	NC*
Female	0.33	0	NC*	Female	0.22	0	NC*
				Total	0.92	1	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	2.37	0	NC*				
Female	1.49	3	NC*	Female	0.57	0	NC*
Total	3.86	3	NC*				
<b>Esophagus</b>			Pa	ancreas			
Male	0.33	1	NC*	Male	0.34	1	NC*
Female	0.08	0	NC*	Female	0.25	0	NC*
Total	0.41	1	NC*	Total	0.59	1	NC*
<b>Hodgkin's Dise</b>	<u>ase</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.15	0	NC*	Male	5.22	1	NC*
Female	0.11	0	NC*				
Total	0.27	0	NC*				
Kidney and Rer	<u>nal Pelvis</u>		St	omach			
Male	0.57	0	NC*	Male	0.39	0	NC*
Female	0.26	0	NC*	Female	0.16	0	NC*
Total	0.83	0	NC*	Total	0.55	0	NC*
<u>Larynx</u>				<u>estis</u>			
Male	0.37	0	NC*	Male	0.22	0	NC*
Female	0.08	0	NC*				
Total	0.45	0	NC*				
<u>Leukemia</u>				hyroid			
Male	0.38	0	NC*	Male	0.10	0	NC*
Female	0.22	0	NC*	Female	0.23	1	NC*
Total	0.60	0	NC*	Total	0.33	1	NC*
Liver and Intral	hepatic Bile I	<u>Ducts</u>		teri, Corpus	and Uterus,	<u>NOS</u>	
Male	0.16	0	NC*				
Female	0.05	0	NC*	Female	0.86	1	NC*
Total	0.21	0	NC*				
<b>Lung and Brond</b>				ll Sites / Typ			
Male	3.10	2	NC*	Male	18.35	11	60
Female	1.68	1	NC*	Female	13.42	11	82
Total	4.78	3	NC*	Total	31.77	22	69

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

## BOLTON

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR		
Bladder, Urinar	<b>Y</b>		$\underline{\mathbf{M}}$	elanoma of	<u>Skin</u>				
Male	2.05	3	NC*	Male	1.26	3	NC*		
Female	0.59	1	NC*	Female	0.94	1	NC*		
Total	2.64	4	NC*	Total	2.20	4	NC*		
<b>Brain and Cent</b>	ral Nervous S	<u>System</u>	Multiple Myeloma						
Male	0.87	1	NC*	Male	0.39	0	NC*		
Female	0.70	1	NC*	Female	0.28	0	NC*		
Total	1.58	2	NC*	Total	0.67	0	NC*		
<b>Breast</b>			Non-Hodgkin's Lymphoma						
Male	0.12	0	NC*	Male	1.72	0	NC*		
Female	12.62	12	95	Female	1.19	1	NC*		
Total	12.74	12	94	Total	2.90	1	NC*		
Cervix Uteri			Oral Cavity and Pharynx						
				Male	1.78	1	NC*		
Female	0.92	1	NC*	Female	0.61	0	NC*		
				Total	2.40	1	NC*		
Colon / Rectum	Colon / Rectum Ovary								
Male	5.46	1	NC*						
Female	3.72	2	NC*	Female	1.59	3	NC*		
Total	9.18	3	NC*						
<b>Esophagus</b>			<u>Pa</u>	ancreas					
Male	0.83	0	NC*	Male	0.82	0	NC*		
Female	0.19	0	NC*	Female	0.62	0	NC*		
Total	1.01	0	NC*	Total	1.44	0	NC*		
Hodgkin's Dise	ease		<u>P</u> 1	rostate					
Male	0.39	1	NC*	Male	11.86	13	110		
Female	0.30	0	NC*						
Total	0.69	1	NC*						
<b>Kidney and Re</b>	nal Pelvis		St	omach					
Male	1.42	0	NC*	Male	0.92	0	NC*		
Female	0.68	2	NC*	Female	0.40	0	NC*		
Total	2.11	2	NC*	Total	1.32	0	NC*		

<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.94	0	NC*	Male	0.55	0	NC*
Female	0.23	0	NC*				
Total	1.16	0	NC*				
<b>Leukemia</b>			<u>T</u> ]	<u>nyroid</u>			
Male	0.93	2	NC*	Male	0.25	0	NC*
Female	0.58	1	NC*	Female	0.65	2	NC*
Total	1.52	3	NC*	Total	0.90	2	NC*
<b>Liver and Int</b>	ahepatic Bile D	ucts	<u>Uteri, Corpus and Uterus, NOS</u>				
Male	0.38	0	NC*				
Female	0.13	0	NC*	Female	2.40	2	NC*
Total	0.51	0	NC*				
<b>Lung and Bro</b>	nchus		<u>A</u> ]	ll Sites / Typ	<u>oes</u>		
Male	7.46	4	NC*	Male	43.54	34	78
Female	4.45	0	NC*	Female	36.17	30	83
Total	11.91	4	NC*	Total	79.71	64	80

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

## **BOSTON**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urina	<u>ary</u>		M	elanoma of S	<u>Skin</u>			
Male	326.72	302	92	Male	189.91	163	86	
Female	138.41	108	78 ~-	Female	176.24	123	70 ^-	
Total	465.13	410	88 #-	Total	366.15	286	78 ^-	
<b>Brain and Cer</b>	ntral Nervou	s System	<u>Multiple Myeloma</u>					
Male	131.91	94	71 ^-	Male	59.19	64	108	
Female	130.35	127	97	Female	61.28	80	131 #+	
Total	262.27	221	84 #-	Total	120.48	144	120 #+	
<b>Breast</b>			No	on-Hodgkin's	s Lymphoma			
Male	17.85	17	95	Male	277.65	365	131 ^+	
Female	2305.16	1975	86 ^-	Female	257.18	245	95	
Total	2323.01	1992	86 ^-	Total	534.83	610	114 ~+	
Cervix Uteri			<u>O</u> :	ral Cavity an	<u>d Pharynx</u>			

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

				Male	236.06	362	153 ^+			
Female	172.19	216	125 ~+	Female	115.34	159	138 ^+			
1 Ciliaic	1/2.17	210	123	Total	351.40	521	148 ^+			
Colon / Rectu	m		O	vary	331.40	321	140 +			
Male	866.85	927	107 #+	<del>, (41_,)</del>						
Female	924.04	935	101	Female	286.44	235	82 ~-			
Total	1790.89	1862	104	Territie	200.11	233	02			
Esophagus	1770.07	1002		ancreas						
Male	112.53	162	144 ^+	Male	122.05	116	95			
Female	45.49	80	176 ^+	Female	144.57	157	109			
Total	158.03	242	153 ^+	Total	266.61	273	102			
Hodgkin's Di	isease		Pr	ostate						
Male	74.26	63	85	Male	1893.16	2007	106 ~+			
Female	62.32	49	79							
Total	136.58	112	82 #-							
Kidney and I	Kidney and Renal Pelvis Stomach									
Male	199.26	193	97	Male	145.83	194	133 ^+			
Female	132.65	132	100	Female	102.30	123	120			
Total	331.91	325	98	Total	248.12	317	128 ^+			
<u>Larynx</u>			Te	<u>estis</u>						
Male	122.37	175	143 ^+	Male	123.61	84	68 ^-			
Female	37.10	51	137 #+							
Total	159.47	226	142 ^+							
<b>Leukemia</b>			<u>Tl</u>	<u>nyroid</u>						
Male	144.02	131	91	Male	42.37	41	97			
Female	121.48	100	82	Female	124.24	160	129 ~+			
Total	265.50	231	87 #-	Total	166.62	201	121 #+			
Liver and Int	rahepatic Bil	e Ducts		t <mark>eri, Corpus</mark>	and Uterus, N	NOS				
Male	55.70	86	154 ^+							
Female	28.31	39	138	Female	417.75	373	89 #-			
Total	84.02	125	149 ^+							
<b>Lung and Bro</b>				ll Sites / Ty						
Male	1070.06	1354	127 ^+	Male	6715.21	7633	114 ^+			
Female	841.12	902	107 #+	Female	7147.86	6994	98			
Total	1911.18	2256	118 ^+	Total	13863.07	14627	106 ^+			

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when  $\mathbf{Obs} < 5$ 

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **BOURNE**Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	Obs	SIR
Bladder, Urinar	<del></del>			<u>lelanoma of</u>			
Male	13.47	15	111	Male	6.75	7	104
Female	4.97	4	NC*	Female	5.38	8	149
Total	18.44	19	103	Total	12.13	15	124
<b>Brain and Cent</b>				<u>lultiple Mye</u>			
Male	4.51	6	133	Male	2.42	1	NC*
Female	4.19	5	119	Female	2.21	5	226
Total	8.70	11	126	Total	4.63	6	129
<b>Breast</b>					's Lymphom	_	
Male	0.71	1	NC*	Male	9.86	9	91
Female	76.96	76	99	Female	8.77	15	171
Total	77.67	77	99	Total	18.63	24	129
Cervix Uteri			<u>o</u>	ral Cavity a	nd Pharynx		
				Male	8.78	13	148
Female	4.80	8	167	Female	3.93	3	NC*
				Total	12.71	16	126
Colon / Rectum	<u>.</u>		<u>O</u>	<u>vary</u>			
Male	35.77	40	112				
Female	33.44	30	90	Female	9.27	7	76
Total	69.21	70	101				
<b>Esophagus</b>			Pa	ancreas			
Male	4.49	7	156	Male	4.90	8	163
Female	1.66	0	NC*	Female	5.25	6	114
Total	6.15	7	114	Total	10.15	14	138
Hodgkin's Dise	ease		<u>P</u> 1	<u>rostate</u>			
Male	2.08	4	NC*	Male	80.60	96	119
Female	1.62	2	NC*				
Total	3.70	6	162				
Kidney and Re	nal Pelvis		St	<u>comach</u>			
Male	7.71	7	91	Male	5.89	5	85
Female	4.62	5	108	Female	3.66	2	NC*
Total	12.33	12	97	Total	9.55	7	73
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	4.81	5	104	Male	3.00	4	NC*
Female	1.30	1	NC*				
Total	6.10	6	98				
<b>Leukemia</b>			<u>T</u>	<u>hyroid</u>			
Male	5.35	3	NC*	Male	1.26	0	NC*
Female	4.02	4	NC*	Female	3.35	5	149
Total	9.36	7	75	Total	4.61	5	108
<b>Liver and Intra</b>	hepatic Bile	<u>Ducts</u>	$\underline{\mathbf{U}}$	teri, Corpus	and Uterus,	<b>NOS</b>	

Male	2.18	4	NC*				
Female	1.00	0	NC*	Female	14.43	17	118
Total	3.18	4	NC*				
<b>Lung and Bro</b>	nchus	All Sites / Types					
Male	43.63	46	105	Male	266.91	301	113 #+
Female	30.05	45	150 #+	Female	242.95	269	111
Total	73.68	91	124	Total	509.85	570	112 ~+

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **BOXBOROUGH**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	Obs	SIR
Bladder, Urinary	,		M	lelanoma of	<u>Skin</u>		
Male	1.61	1	NC*	Male	1.18	0	NC*
Female	0.51	0	NC*	Female	0.98	2	NC*
Total	2.12	1	NC*	Total	2.15	2	NC*
<b>Brain and Centra</b>	al Nervous	System	M	ultiple Mye	<u>loma</u>		
Male	0.86	1	NC*	Male	0.31	0	NC*
Female	0.70	1	NC*	Female	0.24	2	NC*
Total	1.55	2	NC*	Total	0.55	2	NC*
<b>Breast</b>			No	on-Hodgkin'	s Lymphom	<u>a</u>	
Male	0.10	0	NC*	Male	1.63	1	NC*
Female	12.04	15	125	Female	1.11	1	NC*
Total	12.13	15	124	Total	2.74	2	NC*
Cervix Uteri			<u>O</u> :	ral Cavity ar	nd Pharynx		
				Male	1.57	2	NC*
Female	1.03	1	NC*	Female	0.57	0	NC*
				Total	2.13	2	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	4.29	1	NC*				
Female	3.17	1	NC*	Female	1.57	4	NC*
Total	7.46	2	NC*				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	0.68	0	NC*	Male	0.66	1	NC*

Total	0.84	0	NC*	Total	1.19	1	NC*
<b>Hodgkin's Dise</b>	ase		<u>P</u> 1	<u>rostate</u>			
Male	0.48	0	NC*	Male	8.78	6	68
Female	0.36	0	NC*				
Total	0.84	0	NC*				
Kidney and Rei	nal Pelvis		<u>St</u>	<u>comach</u>			
Male	1.22	0	NC*	Male	0.74	0	NC*
Female	0.62	1	NC*	Female	0.35	0	NC*
Total	1.84	1	NC*	Total	1.08	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.78	1	NC*	Male	0.79	0	NC*
Female	0.21	0	NC*				
Total	0.98	1	NC*				
<b>Leukemia</b>			<u>T</u>	hyroid			
Male	0.85	2	NC*	Male	0.28	0	NC*
Female	0.57	1	NC*	Female	0.75	3	NC*
Total	1.41	3	NC*	Total	1.03	3	NC*
<b>Liver and Intra</b>	hepatic Bile D	<u>ucts</u>	$\mathbf{U}_{1}$	teri, Corpus	and Uterus,	<b>NOS</b>	
Male	0.32	0	NC*				
Female	0.11	0	NC*	Female	2.20	3	NC*
Total	0.44	0	NC*				
<b>Lung and Brono</b>	<u>chus</u>		<u>A</u>	ll Sites / Typ	<u>oes</u>		
Male	5.98	4	NC*	Male	35.94	21	58 #-
Female	3.95	3	NC*	Female	33.89	40	118
Total	9.93	7	70	Total	69.83	61	87

NC\*

Female

0.53

0

NC\*

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

Female

0.16

0

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **BOXFORD**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary	7		$\underline{\mathbf{N}}$	Ielanoma of	<u>Skin</u>		
Male	4.43	2	NC*	Male	2.61	6	230
Female	1.44	0	NC*	Female	1.99	3	NC*

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

Total	5.87	2	NC*	Total	4.59	9	196
<b>Brain and Cent</b>	tral Nervous S	<u>System</u>	M	lultiple Mye	eloma		
Male	1.80	1	NC*	Male	0.82	0	NC*
Female	1.52	1	NC*	Female	0.67	0	NC*
Total	3.32	2	NC*	Total	1.49	0	NC*
<b>Breast</b>			No	on-Hodgkin	's Lymphoma	<u>a</u>	
Male	0.25	0	NC*	Male	3.60	6	167
Female	27.35	30	110	Female	2.74	2	NC*
Total	27.60	30	109	Total	6.34	8	126
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	3.66	3	NC*
Female	1.88	0	NC*	Female	1.35	0	NC*
				Total	5.01	3	NC*
Colon / Rectum	<u>_</u>		<u>O</u>	<u>vary</u>			
Male	11.82	8	68				
Female	9.28	3	NC*	Female	3.40	3	NC*
Total	21.09	11	52 #-				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	1.73	1	NC*	Male	1.75	0	NC*
Female	0.46	0	NC*	Female	1.51	0	NC*
Total	2.20	1	NC*	Total	3.26	0	NC*
<b>Hodgkin's Disc</b>	ease		<u>P</u> 1	<u>rostate</u>			
Male	0.80	0	NC*	Male	26.29	28	106
Female	0.62	0	NC*				
Total	1.42	0	NC*				
Kidney and Re	nal Pelvis		St	<u>omach</u>			
Male	2.98	2	NC*	Male	1.97	1	NC*
Female	1.53	1	NC*	Female	1.01	1	NC*
Total	4.52	3	NC*	Total	2.97	2	NC*
<b>Larynx</b>			<u>T</u>	<u>estis</u>			
Male	1.95	0	NC*	Male	1.13	0	NC*
Female	0.48	0	NC*				
Total	2.44	0	NC*				
<b>Leukemia</b>			<u>T</u>	<u>hyroid</u>			
Male	1.96	1	NC*	Male	0.51	2	NC*
Female	1.33	1	NC*	Female	1.33	0	NC*
Total	3.29	2	NC*	Total	1.84	2	NC*
<b>Liver and Intra</b>	hepatic Bile l	<u>Ducts</u>	$\underline{\mathbf{U}}_{1}$	teri, Corpus	and Uterus,	<b>NOS</b>	
Male	0.81	0	NC*				
Female	0.30	0	NC*	Female	5.18	4	NC*
Total	1.11	0	NC*				
<b>Lung and Bron</b>	<u>chu</u> s		<u>A</u> ]	ll Sites / Ty			
Male	15.94	6	38 ~-	Male	93.45	68	73 ~-
Female	9.96	3	NC*	Female	80.89	60	74 #-
Total	25.90	9	35 ^-	Total	174.34	128	73 ^-

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

Exp

~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

Obs

^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

SIR

#### **BOYLSTON**

#### Cancer Incidence by Sex, 1990 - 1995

## **Expected and Observed Case Counts, with Standardized Incidence Ratios**

Exp

Obs

**SIR** 

	Exp	Ous	SIK		Exp	Obs	SII
Bladder, Urinar	<b>Y</b>		$\mathbf{M}$	lelanoma of	<u>Skin</u>		
Male	2.48	1	NC*	Male	1.44	3	NC*
Female	0.81	0	NC*	Female	1.10	0	NC*
Total	3.29	1	NC*	Total	2.55	3	NC*
<b>Brain and Cent</b>	ral Nervous	<u>System</u>	M	ultiple Mye	<u>loma</u>		
Male	0.99	1	NC*	Male	0.46	1	NC*
Female	0.82	0	NC*	Female	0.37	0	NC*
Total	1.81	1	NC*	Total	0.83	1	NC*
<b>Breast</b>			No	on-Hodgkin'	s Lymphoma	<u>a</u>	
Male	0.14	0	NC*	Male	2.03	3	NC*
Female	14.98	20	133	Female	1.54	0	NC*
Total	15.12	20	132	Total	3.57	3	NC*
Cervix Uteri			<u>O</u> :	ral Cavity aı	<u>nd Pharynx</u>		
				Male	1.95	3	NC*
Female	1.06	1	NC*	Female	0.74	0	NC*
				Total	2.69	3	NC*
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	6.59	6	91				
Female	5.25	3	NC*	Female	1.86	1	NC*
Total	11.84	9	76				
<b>Esophagus</b>				ancreas			
Male	0.93	5	538 ~+	Male	0.96	3	NC*
Female	0.26	1	NC*	Female	0.85	0	NC*
Total	1.19	6	503 ~+	Total	1.81	3	NC*
<b>Hodgkin's Dise</b>				<u>rostate</u>			
Male	0.47	1	NC*	Male	14.45	17	118
Female	0.35	0	NC*				
Total	0.83	1	NC*				
Kidney and Re				<u>omach</u>			
Male	1.61	1	NC*	Male	1.10	1	NC*
Female	0.85	1	NC*	Female	0.57	0	NC*
Total	2.46	2	NC*	Total	1.67	1	NC*

		<u>T</u>	<u>estis</u>			
1.03	0	NC*	Male	0.71	1	NC*
0.26	0	NC*				
1.29	0	NC*				
		<u>Tl</u>	<u>nyroid</u>			
1.08	3	NC*	Male	0.30	0	NC*
0.72	1	NC*	Female	0.75	1	NC*
1.80	4	NC*	Total	1.04	1	NC*
rahepatic Bile D	<u>ucts</u>	<u>Uteri, Corpus and Uterus, NOS</u>				
0.44	0	NC*				
0.17	0	NC*	Female	2.82	5	177
0.61	0	NC*				
onchus		<u>A</u> ]	ll Sites / Typ	<u>oes</u>		
8.61	8	93	Male	51.49	63	122
5.55	5	90	Female	44.78	40	89
14.16	13	92	Total	96.27	103	107
	0.26 1.29 1.08 0.72 1.80 rahepatic Bile D 0.44 0.17 0.61 onchus 8.61 5.55	0.26 0 1.29 0  1.08 3 0.72 1 1.80 4  rahepatic Bile Ducts  0.44 0 0.17 0 0.61 0  onchus  8.61 8 5.55 5	1.03 0 NC* 0.26 0 NC* 1.29 0 NC*  1.08 3 NC* 0.72 1 NC* 1.80 4 NC*  rahepatic Bile Ducts 0.44 0 NC* 0.17 0 NC* 0.61 0 NC* onchus 8.61 8 93 5.55 5 90	0.26       0       NC*         1.29       0       NC*         Thyroid         1.08       3       NC*       Male         0.72       1       NC*       Female         1.80       4       NC*       Total         rahepatic Bile Ducts         0.44       0       NC*         0.17       0       NC*       Female         0.61       0       NC*         onchus       All Sites / Type         8.61       8       93       Male         5.55       5       90       Female	1.03 0 NC* Male 0.71 0.26 0 NC* 1.29 0 NC*  Thyroid  1.08 3 NC* Male 0.30 0.72 1 NC* Female 0.75 1.80 4 NC* Total 1.04  rahepatic Bile Ducts  0.44 0 NC* 0.17 0 NC* Female 2.82 0.61 0 NC*  nchus  8.61 8 93 Male 51.49 5.55 5 90 Female 44.78	1.03 0 NC* Male 0.71 1 0.26 0 NC* 1.29 0 NC*  Thyroid  1.08 3 NC* Male 0.30 0 0.72 1 NC* Female 0.75 1 1.80 4 NC* Total 1.04 1  rahepatic Bile Ducts  0.44 0 NC*  0.17 0 NC* Female 2.82 5 0.61 0 NC*  nchus  8.61 8 93 Male 51.49 63 5.55 5 90 Female 44.78 40

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **BRAINTREE**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	Obs	SIR		
Bladder, Urina	<u>ry</u>		M	lelanoma of	<u>Skin</u>				
Male	29.18	31	106	Male	14.49	13	90		
Female	12.11	12	99	Female	12.37	11	89		
Total	41.29	43	104	Total	26.86	24	89		
<b>Brain and Cen</b>	tral Nervous	al Nervous System Multiple Myeloma							
Male	9.41	6	64	Male	5.25	5	95		
Female	9.51	8	84	Female	5.34	1	NC*		
Total	18.92	14	74	Total	10.59	6	57		
<b>Breast</b>			No	on-Hodgkin'	's Lymphoma				
Male	1.54	3	NC*	Male	20.85	18	86		
Female	181.68	217	119 #+	Female	20.79	20	96		
Total	183.22	220	120 ~+	Total	41.64	38	91		
Cervix Uteri	Oral Cavity and Pharynx								

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

				Male	19.30	18	93	
Female	10.68	13	122	Female	9.38	10	107	
				Total	28.69	28	98	
Colon / Rectur	<u>n</u>		0	<u>vary</u>				
Male		98	127 #+					
Female	81.50	85	104	Female	21.59	18	83	
Total	158.97	183	115					
<b>Esophagus</b>			Pa	ancreas				
Male	9.88	12	121	Male	10.67	6	56	
Female	4.05	8	198	Female	12.68	8	63	
Total	13.93	20	144	Total	23.35	14	60	
<b>Hodgkin's Dis</b>	sease		<u>P</u> 1	<u>rostate</u>				
Male	4.04	2	NC*	Male	175.02	218	125 ~+	
Female	3.33	4	NC*					
Total	7.37	6	81					
Kidney and R	enal Pelvis		St	omach				
Male	16.76	16	95	Male	12.76	9	71	
Female	10.85	10	92	Female	8.99	6	67	
Total	27.60	26	94	Total	21.75	15	69	
<b>Larynx</b>			<u>T</u>	<u>estis</u>				
Male	10.64	4	NC*	Male	5.67	4	NC*	
Female	3.09	3	NC*					
Total	13.73	7	51					
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>				
Male	11.19	12	107	Male	2.60	2	NC*	
Female	9.23	7	76	Female	7.28	12	165	
Total	20.42	19	93	Total	9.87	14	142	
<b>Liver and Intr</b>	ahepatic Bile	<b>Ducts</b>		teri, Corpus	s and Uterus,	<b>NOS</b>		
Male	4.73	5	106					
Female	2.37	3	NC*	Female	34.21	30	88	
Total	7.10	8	113					
<b>Lung and Bro</b>				ll Sites / Ty				
Male	95.36	95	100	Male	576.51	627	109 #+	
Female	70.70	68	96	Female	574.93	580	101	
Total	166.06	163	98	Total	1151.44	1207	105	

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# **BREWSTER**

# Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	_			<u>lelanoma of</u>		10	240
Male	10.96	6	55 NC*	Male	4.81	12	249 ~+
Female	3.70	4	NC*	Female	3.61	5	138
Total	14.66	10 System	68 M	Total	8.43	17	202 #+
Brain and Cent Male	3.00	<u>1</u>	NC*	<mark>Iultiple Mye</mark> Male	1.94	1	NC*
Female	2.84	7	246	Female	1.63	0	NC*
Total	5.84	8	137	Total	3.57	1	NC*
Breast	3.04	O			's Lymphom		NC
Male	0.55	1	NC*	Male	7.05	<b>4</b> 7	99
Female	54.04	55	102	Female	6.29	5	79
Total	54.60	56	103	Total	13.34	12	90
Cervix Uteri	31.00	30		ral Cavity a		12	70
CCI VIA C CCI I			<u> </u>	Male	6.39	5	78
Female	3.07	1	NC*	Female	2.82	2	NC*
1 chiaic	3.07	1	110	Total	9.21	7	76
Colon / Rectum	1		0	vary	7.21	,	70
Male	29.06	24	83	<u>, , , , , , , , , , , , , , , , , , , </u>			
Female	24.89	19	76	Female	6.38	3	NC*
Total	53.95	43	80		5.5 5		-,-
Esophagus			Pa	ancreas			
Male	3.47	1	NC*	Male	3.87	1	NC*
Female	1.25	2	NC*	Female	3.89	3	NC*
Total	4.72	3	NC*	Total	7.77	4	NC*
Hodgkin's Dise	ease		<u>P</u> 1	rostate			
Male	1.12	2	NC*	Male	67.11	81	121
Female	0.96	1	NC*				
Total	2.08	3	NC*				
Kidney and Re	nal Pelvis		St	<u>omach</u>			
Male	5.79	5	86	Male	4.74	1	NC*
Female	3.31	4	NC*	Female	2.72	1	NC*
Total	9.10	9	99	Total	7.46	2	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	3.67	3	NC*	Male	1.37	0	NC*
Female	0.93	0	NC*				
Total	4.60	3	NC*				
<b>Leukemia</b>			<u>T</u>	<u>hyroid</u>			
Male	3.86	5	130	Male	0.75	0	NC*
Female	2.76	2	NC*	Female	2.07	0	NC*
Total	6.62	7	106	Total	2.82	0	NC*
Liver and Intra	hepatic Bile	<u>Ducts</u>	$\underline{\mathbf{U}}_{1}$	teri, Corpus	and Uterus,	NOS	

Male	1.67	0	NC*					
Female	0.73	2	NC*	Female	10.29	13	126	
Total	2.40	2	NC*					
<b>Lung and Brono</b>	<u>chu</u> s		<u>A</u> l	ll Sites / Ty	pes			
Male	34.51	24	70	Male	209.58	186	89	
Female	21.78	20	92	Female	173.00	159	92	
Total	56.29	44	78	Total	382.59	345	90	

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **BRIDGEWATER**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	lelanoma of	<u>Skin</u>		
Male	11.51	8	69	Male	7.89	2	NC*
Female	3.80	7	184	Female	5.57	2	NC*
Total	15.31	15	98	Total	13.46	4	NC*
<b>Brain and Cen</b>	tral Nervous	<b>System</b>	$\underline{\mathbf{M}}$	ultiple Mye	<u>loma</u>		
Male	5.69	3	NC*	Male	2.15	1	NC*
Female	4.16	3	NC*	Female	1.71	0	NC*
Total	9.84	6	61	Total	3.86	1	NC*
<b>Breast</b>			No	on-Hodgkin	's Lymphom	<u>a</u>	
Male	0.67	0	NC*	Male	11.36	11	97
Female	70.52	66	94	Female	7.45	10	134
Total	71.20	66	93	Total	18.80	21	112
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	9.87	12	122
Female	5.61	4	NC*	Female	3.46	3	NC*
				Total	13.33	15	112
Colon / Rectun	<u>n</u>		<u>O</u>	<u>vary</u>			
Male	30.68	24	78				
Female	24.89	23	92	Female	8.97	14	156
Total	55.57	47	85				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	4.38	10	228 #+	Male	4.56	2	NC*

Total	5.60	11	196	Total	8.52	7	82
<b>Hodgkin's Disc</b>	ease		<u>P</u> 1	<u>rostate</u>			
Male	3.45	0	NC*	Male	65.07	66	101
Female	2.09	2	NC*				
Total	5.54	2	NC*				
Kidney and Re	nal Pelvis		St	tomach			
Male	7.96	10	126	Male	5.23	5	96
Female	3.96	6	152	Female	2.75	3	NC*
Total	11.92	16	134	Total	7.98	8	100
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	4.90	5	102	Male	5.98	2	NC*
Female	1.15	2	NC*				
Total	6.05	7	116				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	5.75	2	NC*	Male	1.95	2	NC*
Female	3.74	3	NC*	Female	4.11	4	NC*
Total	9.49	5	53	Total	6.07	6	99
<b>Liver and Intra</b>	hepatic Bile I	<u>Ducts</u>	$\mathbf{U}_{1}$	teri, Corpus	s and Uterus	, NOS	
Male	2.16	0	NC*				
Female	0.81	1	NC*	Female	12.77	15	117
Total	2.97	1	NC*				
<b>Lung and Bron</b>	<u>chu</u> s		<u>A</u>	ll Sites / Ty	pes		
Male	40.27	40	99	Male	251.31	223	89
Female	24.75	27	109	Female	212.55	218	103
Total	65.02	67	103	Total	463.86	441	95

NC\*

Female

3.96

5

126

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

Female

1.22

1

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

#### **BRIMFIELD**

#### Cancer Incidence by Sex, 1990 - 1995

	<b>Exp</b>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary	7		$\underline{\mathbf{N}}$	Ielanoma of	<u>Skin</u>		
Male	2.39	6	251	Male	1.22	0	NC*
Female	0.76	1	NC*	Female	0.90	1	NC*

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

Total	3.15	7	222	Total	2.12	1	NC*
Brain and Cent				lultiple Mye		_	-,-
Male	0.81	2	NC*	Male	0.43	2	NC*
Female	0.69	0	NC*	Female	0.34	0	NC*
Total	1.51	2	NC*	Total	0.77	2	NC*
Breast					's Lymphoma		
Male	0.13	0	NC*	Male	1.75	2	NC*
Female	12.55	12	96	Female	1.37	2	NC*
Total	12.68	12	95	Total	3.11	4	NC*
Cervix Uteri				ral Cavity a			
				Male	1.62	2	NC*
Female	0.83	1	NC*	Female	0.64	1	NC*
				Total	2.26	3	NC*
Colon / Rectum	1		0	vary			
Male	6.31	3	NC*				
Female	5.00	5	100	Female	1.53	2	NC*
Total	11.31	8	71				
<b>Esophagus</b>			Pa	ancreas			
Male	0.82	0	NC*	Male	0.87	1	NC*
Female	0.25	0	NC*	Female	0.79	0	NC*
Total	1.07	0	NC*	Total	1.66	1	NC*
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.36	0	NC*	Male	13.80	14	101
Female	0.28	0	NC*				
Total	0.64	0	NC*				
Kidney and Re	nal Pelvis		St	<u>comach</u>			
Male	1.38	2	NC*	Male	1.06	1	NC*
Female	0.74	2	NC*	Female	0.55	1	NC*
Total	2.11	4	NC*	Total	1.60	2	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.88	0	NC*	Male	0.50	0	NC*
Female	0.22	1	NC*				
Total	1.09	1	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	0.96	0	NC*	Male	0.22	0	NC*
Female	0.64	0	NC*	Female	0.58	0	NC*
Total	1.60	0	NC*	Total	0.80	0	NC*
<b>Liver and Intra</b>	<u>thepatic Bile I</u>	<u>Ducts</u>	$\underline{\mathbf{U}}_{1}$	teri, Corpus	and Uterus,	<b>NOS</b>	
Male	0.39	0	NC*				
Female	0.15	0	NC*	Female	2.36	0	NC*
Total	0.54	0	NC*				
<b>Lung and Bron</b>	<u>chu</u> s			ll Sites / Ty	pes		
Male	7.67	5	65	Male	46.89	41	87
Female	4.78	3	NC*	Female	38.74	35	90
Total	12.45	8	64	Total	85.62	76	89

**Obs** = observed case count

**SIR** = standardized incidence ratio [  $(\mathbf{Obs} / \mathbf{Exp}) \times 100$ ]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **BROCKTON**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR		
Bladder, Urina	<u>ry</u>		M	lelanoma of	<u>Skin</u>				
Male	61.90	63	102	Male	32.76	35	107		
Female	25.53	25	98	Female	28.93	24	83		
Total	87.43	88	101	Total	61.68	59	96		
<b>Brain and Cen</b>	tral Nervous	<b>System</b>	M	lultiple Mye	<u>loma</u>				
Male	22.46	31	138	Male	11.20	8	71		
Female	22.18	23	104	Female	11.24	7	62		
Total	44.64	54	121	Total	22.44	15	67		
<b>Breast</b>			No	on-Hodgkin	's Lymphoma				
Male	3.31	4	NC*	Male	47.54	42	88		
Female	400.06	343	86 ~-	Female	45.47	38	84		
Total	403.38	347	86 ~-	Total	93.01	80	86		
Cervix Uteri			Oral Cavity and Pharynx						
				Male	42.51	48	113		
Female	26.53	39	147 #+	Female	20.38	18	88		
				Total	62.89	66	105		
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>					
Male	164.08	144	88						
Female	171.57	138	80 ~-	Female	48.73	55	113		
Total	335.65	282	84 ~-						
<b>Esophagus</b>			<u>Pa</u>	ancreas					
Male	21.16	20	95	Male	22.73	19	84		
Female	8.45	13	154	Female	26.64	19	71		
Total	29.61	33	111	Total	49.36	38	77		
<b>Hodgkin's Dis</b>	<u>ease</u>		<u>P</u> 1	<u>rostate</u>					
Male	10.90	4	NC*	Male	362.15	342	94		
Female	9.23	9	97						
Total	20.13	13	65						
Kidney and Re	enal Pelvis		St	<u>omach</u>					
Male	36.54	42	115	Male	27.33	34	124		
Female	23.56	27	115	Female	19.04	15	79		
Total	60.11	69	115	Total	46.36	49	106		

<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	22.80	14	61	Male	16.14	18	112
Female	6.58	14	213 #+				
Total	29.38	28	95				
Leukemia			<u>T</u> ]	hyroid			
Male	25.93	28	108	Male	6.46	5	77
Female	21.41	17	79	Female	18.80	19	101
Total	47.33	45	95	Total	25.26	24	95
Liver and Inti	rahepatic Bile	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	<u>s and Uterus,</u>	NOS	
Liver and Inti Male	rahepatic Bile 10.26	Ducts 8	78	teri, Corpus	s and Uterus,	<u>NOS</u>	
				<b>teri, Corpus</b> Female	73.69	<b>NOS</b> 72	98
Male	10.26	8	78				98
Male Female	10.26 5.12 15.38	8 11	78 215 #+ 124		73.69		98
Male Female Total	10.26 5.12 15.38	8 11	78 215 #+ 124	Female	73.69		98 101
Male Female Total Lung and Bro	10.26 5.12 15.38 enchus	8 11 19	78 215 #+ 124 <u>A</u>	Female	73.69	72	
Male Female Total Lung and Bro Male	10.26 5.12 15.38 enchus 201.52	8 11 19 255	78 215 #+ 124 <u>Al</u> 127 ^+	Female  Il Sites / Ty  Male	73.69  pes 1239.07	72 1257	101

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} <= 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} <= 0.001$  level, as well as at the  $\mathbf{p} <= 0.05$  and  $\mathbf{p} <= 0.01$  levels

#### **BROOKFIELD**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinar	<b>y</b>		$\underline{\mathbf{M}}$	lelanoma of S	<u>Skin</u>		
Male	2.52	4	NC*	Male	1.24	1	NC*
Female	0.85	0	NC*	Female	0.94	0	NC*
Total	3.37	4	NC*	Total	2.19	1	NC*
<b>Brain and Cent</b>	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	lultiple Myel	<u>oma</u>		
Male	0.82	0	NC*	Male	0.45	0	NC*
Female	0.75	1	NC*	Female	0.38	0	NC*
Total	1.57	1	NC*	Total	0.83	0	NC*
<b>Breast</b>			N	on-Hodgkin'	s Lymphom	<u>a</u>	
Male	0.13	0	NC*	Male	1.80	1	NC*
Female	13.55	11	81	Female	1.52	1	NC*
Total	13.68	11	80	Total	3.33	2	NC*
Cervix Uteri			<u>o</u>	ral Cavity an	d Pharynx		

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

				Male	1.64	3	NC*	
Female	0.85	4	NC*	Female	0.70	0	NC*	
				Total	2.34	3	NC*	
Colon / Rectun	<u>1</u>		<u>o</u>	<u>vary</u>				
Male	6.66	8	120					
Female	5.66	4	NC*	Female	1.64	1	NC*	
Total	12.32	12	97					
<b>Esophagus</b>			Pa	<u>ancreas</u>				
Male	0.84	0	NC*	Male	0.91	1	NC*	
Female	0.29	0	NC*	Female	0.91	0	NC*	
Total	1.12	0	NC*	Total	1.82	1	NC*	
<b>Hodgkin's Dis</b>	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	0.36	1	NC*	Male	15.02	9	60	
Female	0.29	1	NC*					
Total	0.66	2	NC*					
Kidney and Re	enal Pelvis		St	omach_				
Male	1.42	1	NC*	Male	1.10	1	NC*	
Female	0.83	1	NC*	Female	0.61	0	NC*	
Total	2.25	2	NC*	Total	1.71	1	NC*	
Larynx			T	estis				
Male	0.90	3	NC*	Male	0.51	2	NC*	
Female	0.24	1	NC*					
Total	1.14	4	NC*					
Leukemia			T	hyroid				
Male	0.98	3	NC*	Male	0.22	0	NC*	
Female	0.70	1	NC*	Female	0.60	3	NC*	
Total	1.68	4	NC*	Total	0.82	3	NC*	
Liver and Intra	ahepatic Bile I	Oucts	U	teri, Corpus	and Uterus,	NOS		
Male	0.40	1	NC*			<u></u>		
Female	0.18	1	NC*	Female	2.59	3	NC*	
Total	0.58	2	NC*					
Lung and Bron	nchus		$\mathbf{A}$	ll Sites / Ty	pes			
Male	8.09	10	124	Male	49.48	52	105	
Female	5.45	3	NC*	Female	42.63	36	84	
Total	13.54	13	96	Total	92.11	88	96	

**Obs** = observed case count

SIR = standardized incidence ratio [ (Obs / Exp) X 100]

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>+</sup> indicates number of observed cases is statistically significantly higher than the expected number of cases

<sup>-</sup> indicates number of observed cases is statistically significantly lower than the expected number of cases

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} <= 0.01$  level, as well as at the  $\mathbf{p} <= 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

# BROOKLINE

# Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	<u>SIR</u>		<b>Exp</b>	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	41.65	40	96	Male	21.68	22	101
Female	19.08	15	79	Female	21.51	32	149 #+
Total	60.73	55	91	Total	43.19	54	125
<b>Brain and Cen</b>	tral Nervous	<u>System</u>	$\underline{\mathbf{M}}$	lultiple Mye	<u>eloma</u>		
Male	14.02	18	128	Male	7.46	4	NC*
Female	15.59	26	167 #+	Female	8.29	5	60
Total	29.61	44	149 #+	Total	15.75	9	57
<b>Breast</b>			N	on-Hodgkin	<u>'s Lymphoma</u>		
Male	2.21	3	NC*	Male	31.34	31	99
Female	291.48	334	115 #+	Female	33.76	52	154 ~+
Total	293.70	337	115 #+	Total	65.10	83	127 #+
Cervix Uteri			<u>O</u>	ral Cavity a	<u>nd Pharynx</u>		
				Male	27.56	18	65
Female	20.08	19	95	Female	14.77	11	74
				Total	42.33	29	69 #-
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	109.71	120	109				
Female	129.49	143	110	Female	35.38	44	124
Total	239.20	263	110				
<b>Esophagus</b>			<u>Pa</u>	<u>ancreas</u>			
Male	13.79	10	73	Male	14.90	12	81
Female	6.32	7	111	Female	19.81	23	116
Total	20.11	17	85	Total	34.72	35	101
<b>Hodgkin's Dis</b>	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	6.94	10	144	Male	235.59	304	129 ^+
Female	6.85	5	73				
Total	13.79	15	109				
Kidney and Re	enal Pelvis		St	<u>comach</u>			
Male	23.41	26	111	Male	18.50	12	65
Female	16.84	17	101	Female	14.54	15	103
Total	40.25	43	107	Total	33.04	27	82
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	14.64	13	89	Male	10.93	12	110
Female	4.59	2	NC*				
Total	19.23	15	78				
Leukemia			<u>T</u>	hyroid			
Male	16.26	17	105	Male	4.23	9	213
Female	15.20	14	92	Female	14.21	12	84
Total	31.46	31	99	Total	18.44	21	114
<b>Liver and Intra</b>	ahepatic Bile	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus, l	<u>NOS</u>	

Male	6.63	9	136				
Female	3.72	4	NC*	Female	52.55	53	101
Total	10.35	13	126				
<b>Lung and Bro</b>	<u>nchu</u> s		<u>A</u> ]	ll Sites / Ty	pes		
Male	129.81	106	82 #-	Male	809.82	853	105
Female	106.81	95	89	Female	920.67	1003	109 ~+
Total	236.61	201	85 #-	Total	1730.49	1856	107 ~+

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

#### **BUCKLAND**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	Obs	SIR		Exp	Obs	SIR
Bladder, Urinary			M	elanoma of	<u>Skin</u>		
Male	1.33	0	NC*	Male	0.71	1	NC*
Female	0.43	3	NC*	Female	0.54	0	NC*
Total	1.76	3	NC*	Total	1.26	1	NC*
<b>Brain and Central</b>	l Nervou	ıs System	M	ultiple Mye	<u>loma</u>		
Male	0.49	2	NC*	Male	0.24	1	NC*
Female	0.42	2	NC*	Female	0.20	0	NC*
Total	0.91	4	NC*	Total	0.44	1	NC*
<b>Breast</b>			<u>N</u> e	on-Hodgkin	s Lymphom	<u>a</u>	
Male	0.07	0	NC*	Male	1.02	0	NC*
Female	7.59	8	105	Female	0.80	2	NC*
Total	7.66	8	104	Total	1.82	2	NC*
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	0.96	1	NC*
Female	0.50	1	NC*	Female	0.38	0	NC*
				Total	1.34	1	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	3.53	8	226				
Female	2.85	2	NC*	Female	0.93	0	NC*
Total	6.38	10	157				
<b>Esophagus</b>			<u>Pa</u>	ancreas			
Male	0.47	0	NC*	Male	0.50	0	NC*

Esmals	0.14	0	NC*	Esmala	0.46	1	NICY
Female	0.14	0	NC*	Female	0.46	1	NC*
Total	0.61	0	NC*	Total	0.96	1	NC*
<u>Hodgkin's Dise</u>	<u>ase</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.22	0	NC*	Male	7.91	6	76
Female	0.17	0	NC*				
Total	0.39	0	NC*				
Kidney and Ren	<u>nal Pelvis</u>		St	<u>tomach</u>			
Male	0.82	1	NC*	Male	0.58	0	NC*
Female	0.44	0	NC*	Female	0.31	0	NC*
Total	1.26	1	NC*	Total	0.89	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.52	1	NC*	Male	0.32	0	NC*
Female	0.13	0	NC*				
Total	0.65	1	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	0.55	0	NC*	Male	0.14	0	NC*
Female	0.38	1	NC*	Female	0.36	0	NC*
Total	0.93	1	NC*	Total	0.49	0	NC*
<b>Liver and Intra</b>	hepatic Bile D	<u>ucts</u>	$\mathbf{U}_{1}$	teri, Corpus	and Uterus,	NOS	
Male	0.23	0	NC*				
Female	0.09	0	NC*	Female	1.43	1	NC*
Total	0.32	0	NC*				
<b>Lung and Brond</b>	<u>chus</u>		<u>A</u>	ll Sites / Typ	oes		
Male	4.50	4	NC*	Male	27.02	26	96
Female	2.87	3	NC*	Female	23.09	25	108
Total	7.37	7	95	Total	50.11	51	102

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases

#### **BURLINGTON**

#### Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<b>'Y</b>						
Male	14.66	18	123	Male	8.84	8	91
Female	4.94	1	NC*	Female	7.12	17	239 ~+

<sup>\* =</sup> SIR and statistical significance not calculated when Obs < 5

<sup>#</sup> indicates statistical significance at the  $\mathbf{p} \le 0.05$  level

<sup>~</sup> indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level

<sup>^</sup> indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels

Total	19.61	19	97	Total	15.95	25	157 #+
<b>Brain and Cent</b>	ral Nervou	<u>is System</u>	$\underline{\mathbf{M}}$	lultiple My	eloma		
Male	6.09	6	99	Male	2.72	1	NC*
Female	5.32	6	113	Female	2.31	3	NC*
Total	11.41	12	105	Total	5.03	4	NC*
<b>Breast</b>				on-Hodgkin	's Lymphon	<u>na</u>	
Male	0.83	2	NC*	Male	12.41	11	89
Female	96.94	96	99	Female	9.57	10	104
Total	97.77	98	100	Total	21.98	21	96
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	12.00	4	NC*
Female	6.88	11	160	Female	4.76	4	NC*
				Total	16.75	8	48 #-
Colon / Rectum	<u>l</u>		<u>O</u>	<u>vary</u>			
Male	39.22	37	94				
Female	31.59	36	114	Female	12.09	11	91
Total	70.82	73	103				
<b>Esophagus</b>				ancreas			
Male	5.63	5	89	Male	5.81	7	120
Female	1.59	1	NC*	Female	5.21	7	134
Total	7.22	6	83	Total	11.03	14	127
<b>Hodgkin's Disc</b>				<u>rostate</u>			
Male	2.98	1	NC*	Male	88.24	80	91
Female	2.25	2	NC*				
Total	5.23	3	NC*				
Kidney and Re				<u>omach</u>			
Male	9.84	8	81	Male	6.50	6	92
Female	5.40	6	111	Female	3.39	2	NC*
Total	15.24	14	92	Total	9.89	8	81
<u>Larynx</u>				<u>estis</u>			
Male	6.34	5	79	Male	4.63	8	173
Female	1.73	5	289				
Total	8.07	10	124				
Leukemia		_		<u>hyroid</u>			
Male	6.50	8	123	Male	1.86	3	NC*
Female	4.50	6	133	Female	4.84	3	NC*
Total	11.00	14	127	Total	6.70	6	90
Liver and Intra				teri, Corpus	s and Uterus	s, NOS	
Male	2.68	4	NC*				
Female	1.05	1	NC*	Female	18.41	22	119
Total	3.73	5	134				
Lung and Bron				ll Sites / Ty		200	<b>2</b> -
Male	52.70	46	87	Male	312.95	300	96
Female	35.55	22	62 #-	Female	284.54	281	99
Total	88.25	68	77 #-	Total	597.49	581	97

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100]

- \* = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the  $\mathbf{p} \le 0.05$  level
- ~ indicates statistical significance at the  $\mathbf{p} \le 0.01$  level, as well as at the  $\mathbf{p} \le 0.05$  level
- ^ indicates statistical significance at the  $\mathbf{p} \le 0.001$  level, as well as at the  $\mathbf{p} \le 0.05$  and  $\mathbf{p} \le 0.01$  levels